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The view of the lysosome as the terminal end of cellular catabolic pathways has been 
challenged by recent studies showing a central role of this organelle in the control of cell 
function. Here we show that a lysosomal Ca2+ signaling mechanism controls the activities 
of the phosphatase calcineurin and of its substrate TFEB, a master transcriptional 
regulator of lysosomal biogenesis and autophagy. Lysosomal Ca2+ release via mucolipin 1 
(TRPML1) activates calcineurin, which binds and de-phosphorylates TFEB, thus promoting 
its nuclear translocation. Induction of autophagy and lysosomal biogenesis via TFEB 
required TRPML1-mediated calcineurin activation, linking lysosomal calcium signaling to 
both calcineurin regulation and autophagy induction. In addition to the role of TRPML1 
on sustaining transcriptional autophagy program, through the activation of TFEB, we also 
found that TRPML1-activation induces the recruitment of PtdIns(3)P-binding proteins to 
the nascent autophagosome, whereas genetic or pharmacological inhibition of TRPML1 
channel inhibits autophagy initiation. Importantly, alteration of this function has 
pathological consequences, and thus we found that autophagosome formation is 
impaired in human fibroblasts from patients affected of mucolipidosis IV (MLIV; a severe 
lysosomal storage disorder caused by mutations in TRPML1). By using specific compound 
inhibitors during starvation, we found that TRPML1-mediated induction of 
autophagosome biogenesis requires calmodulin, CaMKKβ, and the PtdIns(3)-generating 
enzyme VPS34. Therefore, we hypothezise that during starvation, TRPML1 activation 
releases lysosomal calcium that activates a calcium-depedent pathway involving CaMKKβ 
and the induction of two essential protein complexes involved in autophagy initiation 
such as ULK1 and PIK3C3 complexes.  
In parallel studies, we used high content (HC) screening approaches to identify small 
molecules able to ameliorate the MLIV phenotype. In one of them, we tested whether 
previously identified drugs (150 FDA compounds) inducing TFEB translocation and 
cellular clearance might be active in MLIV patient cells. This screening resulted in the 
identification of 3 drugs able to induce TFEB nuclear translocation confirming the 
importance of the TRPML1-mediated signalling to promote TFEB activity. In addition, only 
one of these hits were able to reduce the pathological accumulation of autophagic 
substrates such as p62 and NBR1 in MLIV human fibroblasts.  In a second independent 
HC-screening, we developed a cell-based assay to identify FDA-drugs able to reduce 
cholesterol accumulation in MLIV cells. We identify 8 small molecules able to reduce 
cholesterol accumulation in MLIV human fibroblasts that will need further 
characterization to define their ability to ameliorate the phenotype of this devastating 
disease. In summary, we found two novel signaling pathways triggered by TRPML1-
dependent lysosomal calcium release that regulate cellular homeostasis by both 
promoting autophagy initiation and sustaining transcriptional programs inducing 
autophagic and lysosomal genes during starvation. Finally, we use part of this knowledge 
to develop cell-based high content screening assays that identified 9 FDA-approved 
compounds able to ameliorate the autophagic impairment and reduce lipid storage in 
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The family of transient receptor potential (TRP) channels is formed by seven subfamilies: 
TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML 
(mucolipin), TRPA (ankyrin) and TRPN (NOMPC-like), with the last one only found in 
invertebrates and fish. These channels are ubiquitously expressed and could be classified 
as non – selective cation channels with only few of them classified as highly selective for 
calcium ions. The Trp gene was firstly identified in Drosophila melanogaster by Montell 
and Rubin in 1989 (Montell and Rubin, 1989). Going through the sequence, TRP family 
members share 35 % of homology except for the ones which come from duplication, like 
TRPC6 and TRPC7, TRPM4 and TRPM5, and TRPV5 and TRPV6, where the homology goes 
from 50 to 80% (Nilius and Owsianik, 2011). 
All TRP proteins have the same structure, they are composed by six transmembrane 
domains with the pore region located within the 5th and 6th transmembrane segments. In 
addition, they present an amino and a carboxyl tail that could vary among channel 
members. For instance, it has been reported that the carboxyl terminal could contain an 
entire catalytic site, like the Nudix hydrolase domain in TRPM2 (Perraud et al., 2001). On 
the other hand, the amino terminal is enriched of ankyrin repeats, the number of repeats 
varies among different TRP members, and the function seems to be connected with 
tetramerization of the channel and interactions with ligands and protein partners 
(Gaudet, 2008). Other additional domains and motifs could be part of the channel 
structure and are strictly connected with the channel function. Generally, these domains 
are coiled coils, calmodulin-binding sites, lipid-interaction domains, EF hands or 
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phosphorylation sites, and are firmly preserved within the same TRP subfamily (Owsianik 
et al., 2006).  
TRPs are principally located on cellular membranes with the only exception for the 
nuclear envelope and the mitochondrial membrane (Nilius and Owsianik, 2011). The 
majority of TRP channels is located on plasma membrane (PM) and is involved in cation 
transport (Ca2+, Mg2+, trace of metal ions) thus, many of them are involved in different 
biological processes such as homeostatic functions, muscle contraction and vasomotor 
control. Generally, for the correct execution of their function TRP channels are associated 
with accessory proteins, for instance TRPV4 interacts with PACSIN3, a protein kinase C 
and casein kinase II substrate, which modulates synaptic vesicular membrane traffic and 
dynamin-mediated endocytic processes in neurons (D'Hoedt et al., 2008, Cuajungco et 
al., 2006). 
In the last decade, several mechanisms have been described for TRP channels activity. 
They could be activated by different stimuli such as membrane voltage, membrane 
phospholipids, phosphorylation and interaction with ligand. Membrane voltage 
activation is generally used by TRP channels involved in sensorial perception (Nilius et al., 
2005, Nilius et al., 2003). This activation takes place thanks to positively charged amino 
acid (aa), like lysine and arginine in the 4th and 5th transmembrane domain (Voets et al., 
2007). Due to their principal location on plasma membranes, it is not a surprise that TRP 
channels are particularly sensitive to membrane phospholipids, as in the case of TRPA1 
and TRPV1 (Kim et al., 2008, Karashima et al., 2008). The phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) is one of the principal phospholipids on plasma membrane and 
with the help of phospholipase C (PLC) and phosphatidylinositol kinases/phosphatases 
could rapidly modify its concentration modulating TRP channels activity (Rohacs and 
Nilius, 2007, Voets and Nilius, 2007, Liu and Qin, 2005). This is true for the cold- and 
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menthol-sensitive TRPM8 and the Ca2+-activated taste-transducing TRPM5 channels. It 
has been shown that the activation of PLC mediated by calcium rapidly reduces the 
PI(4,5)P2 levels leading to a decrease in the affinity of the channel for its ligands (menthol 
for TRPM8 and calcium for TRPM4) (Liu and Qin, 2005, Nilius et al., 2006). In addition, 
also TRPML1, an endo-lysosomal TRP channel is modulated by phospholipids. TRPML1 
could directly interact with PI(3,5)P2 leading to an highly specific channel activation (Dong 
et al., 2010). Two major kinases have been identified as TRP channels modulator by direct 
phosphorylation, and those are protein kinase C (PKC) and protein kinase A (PKA). PKC 
seems to sensitize TRPV1 to its ligand (heat or capsaicin) (Premkumar and Ahern, 2000, 
Bhave et al., 2003) and through phosphorylation of TRPM8 leads to channel inactivation 
(Premkumar et al., 2005). PKA, on the other hand, directly phosphorylates TRPML1 
inducing a reduction in channel activity (Vergarajauregui et al., 2008b). In fact, two serine 
belonging to the PKA consensus motif were found in the C-terminus of TRPML1 
(Vergarajauregui et al., 2008b). Also TRPV1 could be phosphorylated by PKA and this 
phosphorylation potentiates its activity (Bhave et al., 2003). More recently, Brenman and 
colleagues have shown that also the target of rapamycin (TOR), a nutrient sensitive kinase 
that is involved in negative regulation of the autophagic flux, directly phosphorylates the 
Drosophila trpml and inactivates it (Onyenwoke et al., 2015). Finally, the best stimulus 
which activates TRP channels is mediated by the interaction with a large number of 
exogenous and endogenous ligands. For instance, temperature sensitive TRP channels 
prefer plants derived compounds, indeed, TRPV1 is activated by capsaicin (Caterina et al., 
1997), resiniferatoxin (Szallasi et al., 1999), piperine (McNamara et al., 2005) and 
camphor (Xu et al., 2005). Not only plants derived compounds could interact with TRP 
channels, but also a wide range of synthetic ligands are available and the majority of them 
represents useful pharmacological tools to modulate channel activity (Nilius and 
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Owsianik, 2011). Some of these compounds bind to more than one TRP channel, like 2-
aminoethyl diphenylborinate which activates TRPV1, TRPV2 and TRPV3 (Chung et al., 
2004, Hu et al., 2004) and icilin which activates TRPM8 and TRPA1 (McKemy et al., 2002, 
Story et al., 2003). Other compounds exist which are more specific and very selective for 
one TRP channel such as olvanil for TRPV1 (Iida et al., 2003) and 4α-phorbol-12,13-
didecanoate (4α-PDD), lumiphorbols, phorbol-hexonates and GSK 1016790A for TRPV4 
(Watanabe et al., 2002, Klausen et al., 2009, Thorneloe et al., 2008).  
TRPMLs 
The transient receptor potential mucolipin (TRPML) channel group is one of the TRPs 
subfamilies and is formed by three members, TRPML1, TRPML2 and TRPML3 which share 
about 75% of similarity in the amino acid sequence (Di Paola et al., 2017). Being a sub-
group of the TRP channel family these channels share specific structural features like the 
pore-forming re-entrant loop between the 5th and the 6th trans-membrane segment and 
two cytoplasmic amino- and carboxyl- termini (Li et al., 2011), but characteristic features 
of TRPMLs are the large extracellular-intraluminal loop between the 1st and the 2nd 
transmembrane segment and the short cytosolic tails, which range from 61 to 72 aa in 
length. The presence of negatively charged glutamate and aspartate residues within the 
pore region defines TRPMLs selectivity to cations. Since  high similarity in the pore 
sequence of TRPMLs exists, it is likely that differences in their regulation and conductance 
are defined by structural determinants located outside the pore (Di Paola et al., 2017). 
TRPML1 channel structure and function 
MCOLN1 gene and the associated disease mucolipidosis type IV (MLIV) 
Human TRPML1 is encoded by the MCOLN1 gene which is located on chromosome 19 
and, unlike the murine homolog, does not have splicing variants (Falardeau et al., 2002).  
Genetic mutations leading to inactivation of TRPML1 cause a rare genetic disorder called 
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Mucolipidosis Type IV (MLIV). In 2000, three research groups independently identified 
MCOLN1 as the mutated gene causing MLIV (OMIM 252650), an autosomal recessive 
lysosomal storage disease (LSD) characterized by mental retardation, corneal opacities, 
elevated blood gastrin levels, achlorhydria and delayed motor milestones (Bargal et al., 
2000, Berman et al., 1974, Bassi et al., 2000, Sun et al., 2000, Frei et al., 1998, Amir et al., 
1987, Altarescu et al., 2002, Lubensky et al., 1999). Distribution of the disease is relatively 
rare in the whole population with a prevalence of 1 in 40,000 individuals (Altarescu et al., 
2002, Bach, 2001, Kogot-Levin et al., 2009, Bargal et al., 2002). Of note, 70-80% of 
affected individuals were identified as Ashkenazi Jewish (AJ) descent, with carrier 
frequency in AJ population estimated to be 1:100 (Bargal et al., 2000). In individuals 
affected by MLIV, two main mutations, originated from AJ, were isolated. The major AJ 
mutation, present on 72% of the AJ MLIV alleles, is an A>G transition at the 3′ spliceosome 
acceptor site for intron 3 that causes the deletion of exon 4 (Bargal et al., 2000, Bassi et 
al., 2000, Sun et al., 2000, Altarescu et al., 2002), the minor AJ mutation, found on 23% 
of the AJ MLIV alleles, is a 6434 bp genomic deletion that spans exons 1–6 and the first 
12 bp of exon 7 (Altarescu et al., 2002). Other mutations in the MCOLN1 gene account 
for the remaining 5% of affected individuals. These novel mutations have been 
documented as nonsense, missense and one in-frame deletion which generally cause 
milder phenotypes (Sun et al., 2000, Altarescu et al., 2002, Bach, 2001). MCOLN1 is 
ubiquitously transcribed in all tissues, with brain, spleen, liver and heart expressing the 
highest levels of the transcript (Samie et al., 2009). To dissect the role of TRPML1 in 
cellular physiology, many cell-based studies have been performed on MLIV-derived 
fibroblasts or through TRPML1 acute silencing in heterologous cells (Di Paola et al., 2017). 
Early studies on MLIV patient fibroblasts have shown lysosomal accumulation of 
heterogeneous macromolecules, like gangliosides, phospholipids and 
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mucopolysaccharides, which are not due to defects in enzymatic degradation (Bargal and 
Bach, 1988, Bargal and Bach, 1989, Zeigler et al., 1992). Indeed, MLIV fibroblasts as well 
as cells depleted of TRPML1 show defective transport of lipids from acidic organelles to 
the Golgi apparatus or the plasma membrane and a delayed lipid metabolism, which 
causes lysosomal accumulation of substrates and indirectly interferes with other 
transport pathways (Chen et al., 1998, Bargal and Bach, 1997, Pryor et al., 2006, Jansen 
et al., 2001, Thompson et al., 2007, Miedel et al., 2008). Animal models for MLIV disease 
have been generated in mice, C. elegans, and Drosophila showing similar substrate 
accumulation and endo-lysosomal trafficking alterations (Fares and Greenwald, 2001, 
Venkatachalam et al., 2008, Micsenyi et al., 2009). 
Channel structure and regulation  
The late endo-lysosome (LEL) compartment is the primary site of TRPML1 localisation in 
mammalian cells (Pryor et al., 2006, Manzoni et al., 2004). Similar localisation has been 
reported for TRPML1 orthologs in other animal models, such as Drosophila, C. elegans 
and Xenopus (Fares and Greenwald, 2001, Venkatachalam et al., 2008, LaPlante et al., 
2002). TRPML1 can also reach the plasma membrane, through the biosynthetic pathway 
from the Golgi apparatus or by lysosomal exocytosis, a process responsible for the 
repair/reseal of plasma membrane injuries, secretion of lysosomal enzymes or clearance 
of lysosomal content (Pryor et al., 2006, Rodriguez et al., 1997, Medina et al., 2011, Clark 
and Griffiths, 2003, Vergarajauregui and Puertollano, 2006). Lack or dysfunction of 
TRPML1 causes impairment in lysosomal functions, with an abnormal accumulation of 
heterogeneous material in the lysosomes. The discovery of TRPML1 as an endo-lysosomal 
Ca2+-permeable channel has been very relevant for the study of lysosomal biology as Ca2+ 
is an universal second messenger required for many intracellular processes such as 
membrane trafficking, phagocytosis, exocytosis and vesicular fusion (Medina et al., 2011, 
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Sudhof and Rothman, 2009, Li et al., 2013, Cooper and McNeil, 2015). Early studies on 
TRPML1 channel activity relied on the measurement of whole-cell and single channel 
currents using standard voltage-clamp techniques. These measurements showed that 
TRPML1 acts as a non-selective channel permeable to various cations such as Ca2+, Na+ 
and K+ (LaPlante et al., 2002, LaPlante et al., 2004). Although most of these studies were 
performed in vitro and using plasma membrane-mislocalised mutant versions of TRPML1, 
recent work using patch-clamp on isolated lysosomes confirmed that TRPML1 is an 
inwardly rectifying current channel, able to transport cations from the lumen of the 
lysosome, or from the extracellular space, to the cytosol (Xu et al., 2007). Mutagenesis 
studies on the linker between the 4th and 5th transmembrane tracts and the last part of 
the 5th transmembrane tract, led to the identification of the amino acidic residues that 
are critical to modulate channel permeability (Dong et al., 2009). 
In addition to Ca2+, TRPML1 is able to mobilize heavy metals such as Fe2+ and Zn2+ from 
the lumen of the lysosome (Eichelsdoerfer et al., 2010, Dong et al., 2008). Various studies 
reported the existence of a zinc regulatory circuit in which the lysosomal Zn2+-importer 
ZnT4, the Zn2+-responsive transcription factor MTF-1 and TRPML1, which interacts with 
the putative lysosomal Zn2+ extruder TMEM163, contribute to cellular balance of 
chetable Zn2+ in the cell (Kukic et al., 2013, Kukic et al., 2014, Cuajungco et al., 2014). 
These data suggest that accumulation of Fe2+ and Zn2+ might be the deleterious process 
promoting cell death and neurodegeneration in MLIV disease.  
As for many other proteins localised in specific cellular compartments, the correct 
targeting of TRPML1 to the lysosome is probably one of the first mechanisms of 
regulation and quality control. TRPML1 is a 580aa long six-pass transmembrane channel 
with both the N-, and C-termini exposed to the cytoplasm (Fig. 1). The two cytosolic tails 
contain one di-leucine motif each, which dictate targeting of the protein to the LEL 
13 
 
compartment. The N-terminal di-leucine motif (L15L) promotes TRPML1 transport from 
the trans-Golgi network (TGN) to early endosomes and then to lysosomes, through a 
mechanism that requires the adaptor protein (AP)-1. The C-terminal di-leucine motif 
(L577L) instead, signals through AP-2 for the recycling of plasma membrane TRPML1 to 
the LEL compartment (Vergarajauregui and Puertollano, 2006, Miedel et al., 2006). In 
addition, the C565CC palmitoylation motif is involved in TRPML1 recycling by facilitating 
the interaction of the C-terminal endocytic motif with AP-2 (Vergarajauregui and 
Puertollano, 2006). Differently, the R200P201 site in the intraluminal loop is sensitive to 
the enzymatic cut mediated by cathepsin B (CTSB) which inactivates the channel 
generating different forms of the protein (Kiselyov et al., 2005). Likely, inactivation of 
TRPML1 by cleavage is a regulatory mechanism to limit the duration of the channel 
activity. The cytosolic portions of TRPML1 are also the most affected by post-translational 
modifications or binding to regulatory molecules. Protein kinase A (PKA) phosphorylates 
TRPML1 on S557 and S559 in the C-terminal cytosolic domain, inducing a decrease in the 
channel conductance. Because of large distance between the target serines and the pore 
region, it is conceivable that phosphorylation affects the channel activity impairing its 
multimerization (e.g. with other TRPMLs) or interaction with other proteins 
(Vergarajauregui et al., 2008b, Venkatachalam et al., 2006, Curcio-Morelli et al., 2010b). 
Protein kinase D (PKD) is also involved in the phosphorylation of TRPML1 at its C-terminal 
region. This modification seems to be critical for the trafficking of TRPML1 from the Golgi 
apparatus to the lysosome, although the target residues have not yet been identified 
(Marks et al., 2012). In Drosophila, TRPML1 is a target of the lysosome associated TORC1 
kinase, a master regulator of cell growth and metabolism. TORC1 phosphorylates TRPML1 
on two serines, S572 and S576 (Onyenwoke et al., 2015). 
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Once in the lysosome, the highly acidic environment has been proposed to modulate the 
activity of TRPML1. Conflicting reports have shown both activating and inhibitory effect 
of pH on the channel conductance or even postulated a role for TRPML1 in the 
mobilisation of protons out of the lysosome (Xu et al., 2007, Dong et al., 2009, 
Raychowdhury et al., 2004, Soyombo et al., 2006, Cantiello et al., 2005, Goldin et al., 
2008). A very recent study shed new light on the role played by pH in the regulation of 
TRPML1 channel (Li et al., 2017). Li and colleagues resolved the crystal structure of the 
intraluminal loop between the first and the second transmembrane domains of TRPML1. 
This loop is able to form a tetramer, which acts as an intraluminal pore that participates 
in ion transport across the membrane. Interestingly, specific aspartate residues in each 
loop are critical for the channel conductance. Thus, at pH 7.4, the negative charge of 
these aspartate residues inhibits Ca2+ conductance whereas at pH 4.6 the aspartates are 
protonated, promoting conductance. These evidences, collectively suggest that pH 
differently regulates the TRPML1 function depending on the cellular compartment. In the 
lysosomes, the acidic pH favours the release of Ca2+ from the lumen through TRPML1 
activation, whereas on the plasma membrane, the high pH of the extracellular milieu 
inhibits Ca2+ influx (Li et al., 2017).  
Phosphoinositides (PIPs) are important regulators of TRPML1 in membranes. In 
eukaryotes, PIPs metabolism covers a key role in the maintenance of organelle identity, 
intracellular trafficking and other aspects of cell physiology. Different PIPs localise in 
different membrane compartments and this diversification dictates the identity of each 
organelle (Schink et al., 2016). The importance of PIP metabolism in human disease is 
supported by the existence of various disorders caused by mutations in different PI-
metabolising enzymes. Signalling mediated by PIPs is exerted through well-known protein 
domains (PH, PX, FYVE, FERM, etc.) or basic amino acid stretches contained in PIPs-
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recognizing proteins. Membrane PIPs as well as Ca2+ release are both necessary for 
fusion-fission events in intracellular trafficking. As described above, different members of 
TRPC, TRPM and TRPV channel families are regulated by PIPs and TRPMLs undergo the 
same regulation (Rohacs, 2014). The first evidence of such regulation of TRPML1 was 
provided by the activatory role of PI(3,5)P2, a low abundant endo-lysosomal specific PIP 
(Dong et al., 2010). In animal cells, PI(3,5)P2 is generated by the phosphorylation of PI3P 
by the PIKfyve kinase, whereas Sac3/FIG4 and MTMR lipid phosphatases de-
phosphorylate PI(3,5)P2 to PI3P and PI5P, respectively (Tronchere et al., 2004, Gary et al., 
2002). As expected, conversion of PI(3,5)P2 to PI5P, by over-expressing the PI3-
phosphatase MTM1, decreases TRPML1 channel activity (Dong et al., 2010). As already 
mentioned, TRPML1 can also localise to the plasma membrane in which PI(4,5)P2, is 
abundant. Analysis performed on TRPML1 exposed to PI(4,5)P2 showed an inhibitory 
effect on channel gating (Zhang et al., 2012). PI(3,4)P2 and PI(3,4,5)P3 also inhibit 
TRPML1 gating, although with lower efficacy. Both PI(3,5)P2 and PI(4,5)P2 bind to a very 
well conserved aa stretch in the N-terminal region of TRPML1, with R61 and K62 
selectively required for PI(3,5)P2 activation and R41/R42/R43 specifically required for 
PI(4,5)P2 inhibition (Zhang et al., 2012). The importance of PIPs modulation for TRPML1 
activation has been confirmed in a recent work describing the role of the PI(4,5)P2 
phosphatase OCRL on lysosomal function. Upon nutrient starvation, the fusion of 
autophagosomes with lysosomes stimulates the translocation of OCRL from the 
endosomal compartment to the lysosomes, where it interacts with TRPML1. On the 
lysosome, OCRL de-phosphorylates PI(4,5)P2 to PI4P thus sustaining the activation of 
TRPML1 and the progression of the autophagic flux. Interestingly, in Lowe syndrome cells, 
in which OCRL is mutated, TRPML1 activation is delayed, and an accumulation of 
autophagosomal structures is observed. Stimulation by specific activators (Table 1) or 
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over-expression of TRPML1 in these cells can ameliorate the lysosomal phenotype, 
confirming that OCRL is important for TRPML1 channel activity (De Leo et al., 2016). 
  
Figure 1: TRPML1 channel structure consists of six transmembrane (6TM) domains with the amino-terminal 
(NH2) and carboxyl-terminal (COOH) tails facing the cytosol. In this cartoon the major channel 
characteristics are highlighted: the large loop between the 1st and 2nd TM domains, the two di-leucine 
motifs necessaries for channel localisation (in green), the phosphoinositide binding sites (in purple and 
yellow), the two serines phosphorylated by PKA at the C-terminus (in red) the key aa residues in the pore 
region (orange dots), whose mutation leads to gain or loss of function mutant. Reproduced with 
permission from: Wuyang Wang et al. (Wang et al., 2014) 
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TRPML1 biological function 
Lysosomal biogenesis, exocytosis and positioning 
The studies performed on cells and animal models lacking TRPML1 underlined gross 
defects in the LEL compartment. Null mutations in cup-5, the ortholog of MCOLN1 in C. 
elegans, cause impairment in the maturation of lysosomes from late endosomes (Fares 
and Greenwald, 2001, Treusch et al., 2004, Campbell and Fares, 2010). Similar 
accumulation of immature LEL has also been observed in the Drosophila trpml null-model 
(trpml1) and in neuronal cells isolated from TRPML1 KO mice (Venkatachalam et al., 2008, 
Micsenyi et al., 2009). The possible explanation for these alterations could lie into 
vesicular fusion/fission impairment due to abolished TRPML1 channel activity and 
reduced lysosomal Ca2+ release (LaPlante et al., 2002, LaPlante et al., 2004, Pryor et al., 
2000, Miller et al., 2015). The absence of TRPML1 has been correlated to multiple 
trafficking defects such as in the retrograde transport of lactosyl-ceramide to the Golgi 
compartment, in the transport and degradation of different substrates into the 
lysosomes, and in the delivery of lysosomes to the plasma membrane  via exocytosis 
(Chen et al., 1998, Pryor et al., 2006, Thompson et al., 2007, Miedel et al., 2008). The 
latter is still a very intriguing cellular process, as the protein components and the 
regulatory mechanisms modulating it still need to be fully characterised, in particular in 
cells not derived from the hematopoietic lineage. Lysosomal exocytosis is a two-step 
process that initially requires the docking of lysosomes to the close proximity of the PM 
and then the elevation of intracellular Ca2+ levels to favour membrane fusion. The 
lysosomal membrane protein synaptotagmin VII (SytVII) plays a crucial role in the binding 
of Ca2+ and subsequent tethering of lysosomal and plasma membrane SNAREs preceding 
membrane fusion (Martinez et al., 2000, Reddy et al., 2001). Upon release of lysosomal 
content, lipids and lysosomal membrane proteins, including LAMP1 and TRPML1, fuse to 
the plasma membrane and are recycled-back through endocytosis (LaPlante et al., 2002). 
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The first evidence suggesting a role for TRPML1 in lysosomal exocytosis came from 
studies in human MLIV fibroblasts (LaPlante et al., 2006). In this regard and unexpectedly, 
the discovery of the transcription factor EB (TFEB), a master gene for lysosomal 
biogenesis and autophagy, has contributed to confirm the positive role of TRPML1 
channel in lysosomal exocytosis. Indeed, TFEB over-expression is able to induce cellular 
clearance of lysosomal storage in various in vitro and in vivo models of LSDs (Medina et 
al., 2011). The silencing of TRPML1, a direct transcriptional target of TFEB, inhibits 
lysosomal exocytosis while the over-expression of TFEB in MLIV fibroblasts is not able to 
induce lysosomal exocytosis (Medina et al., 2011, Palmieri et al., 2011). Most importantly, 
this discovery raised a novel and promising therapeutic approach to treat LSDs by 
activating lysosomal exocytosis to clear pathological storage (Medina et al., 2011, 
LaPlante et al., 2006). Subsequently, many other research groups have obtained similar 
results and also extended this approach for the clearance of toxic cargoes in more 
common neurodegenerative disorders such as Alzheimer, Parkinson, and Huntington 
disease (Napolitano and Ballabio, 2016, Settembre et al., 2013).  
TRPML1 has also been involved in phagocytosis and clearance of exogenous particles in 
macrophage cells (Dayam et al., 2015, Samie et al., 2013). Upon exposure of cell to 
external particles, TRPML1 is stimulated by endogenous PI(3,5)P2, leading to exocytosis 
of lysosomes near the site of phagocytosis (Samie et al., 2013). Once the particles are 
internalized, TRPML1 activity may promote the fusion of the phagosome with the 
lysosome to stimulate particle degradation (Dayam et al., 2015).  
More recently, TRPML1 has been implicated in the centripetal movement of lysosomes 
upon nutrient starvation (Li et al., 2016). During autophagy (see next paragraph), the 
lysosomes are recruited to the perinuclear area where they become proximal to 
autophagosomes to which they fuse into autolysosomes (Korolchuk et al., 2011). In basal 
19 
 
endocytic conditions, trafficking of lysosomes towards the centre of the cell is mediated 
by a Rab7/RILP/dynein mechanism. Conversely, upon starvation, a PI(3,5)P2/TRPML1-
mediated Ca2+ release activates the Ca2+-binding protein ALG-2, which binds to TRPML1 
and in turn recruits the dynein-dynactin complex for retrograde transport of lysosomes 
(Li et al., 2016, Vergarajauregui et al., 2009). Thus, TRPML1 may control different 
lysosomal functions depending on the position of the lysosome and the specific 
interaction with partner proteins localised in different regions of the cell. For instance, 
TRPML1 activation in a lysosomal pool close to the PM might promote lysosomal 
exocytosis, whereas perinuclear TRPML1-lysosomes might trigger autophagosome-
lysosome fusion. 
Autophagy 
Macroautophagy, hereafter referred to as autophagy, is a multi-step intracellular 
catabolic process which mediates the sequestration of damaged organelles and 
macromolecules into specialised vesicles, named autophagosomes. Mature 
autophagosomes are finally delivered to lysosomes for fusion and degradation of their 
content (Yorimitsu and Klionsky, 2005). Autophagy exists in basal conditions and is further 
activated by cellular stress conditions, such as nutrient deprivation. The main purpose of 
this process is to clear the cells from toxic material and produce nutrients from digested 
macromolecules. In both human fibroblasts derived from MLIV patients and heterologous 
cells depleted of TRPML1, alterations in the autophagic pathway with the elevation of 
lipidated LC3 protein and accumulation of the autophagic substrate SQSTM1/P62 have 
been found (Vergarajauregui et al., 2008a, Jennings et al., 2006). Immunofluorescence 
analysis has shown marked increase in the co-localisation of LC3-puncta with 
SQSTM1/P62 and delayed fusion of autophagosomes with LEL during nutrient deprivation 
(Vergarajauregui et al., 2008a). Similar findings were also described in neuronal cells 
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derived from a MLIV mouse model (Micsenyi et al., 2009, Venugopal et al., 2007, Curcio-
Morelli et al., 2010a).  
Studies performed on Drosophila trpml1 mutants described similar autophagy defects, 
with increased number of autophagosome structures and reduced degradation of cargo 
in autolysosomes (Venkatachalam et al., 2008). In addition, the defect in TRPML1-
mediated Ca2+ release from late endosomes also impairs the fusion of amphisomes 
(single membrane structures derived from the fusion of autophagosomes and late 
endosomes) with lysosomes (Wong et al., 2012). 
Different signalling pathways regulate the execution of the autophagic process, and 
among them, the mTORC1-regulated pathway is probably the most important. mTORC1 
senses amino acid content on the lysosomal surface. In normal nutrient rich conditions 
mTORC1 is active and inhibits autophagy. In Drosophila trpml1 mutants, defective 
vesicular fusion results in lower catabolic activity and reduced amino acid levels. Such 
condition leads to an inhibition of TORC1 mimicking starvation and causing aberrant 
accumulation of autophagic substrates and cell death (Wong et al., 2012).  
A role of TRPML1 in autophagy has also been reported in cup-5 null mutant in C. elegans. 
In addition to the defects in sorting of material from endosomes to lysosomes with its 
aberrant accumulation in large vacuoles, loss-of-function cup-5 mutants results in 
impairment of degradation of autophagy substrates (Fares and Greenwald, 2001, Treusch 
et al., 2004, Sun et al., 2011). Accumulation of T12G3.1 and LGG-1 (SQSTM1/P62 and LC3 
homologues) in enlarged LEL structures indicates that mutations in cup-5 do not affect 
fusion between lysosomes and autophagosomes but interferes with degradation in 
autolysosomes. It has been previously shown that cup-5 null mutation is responsible for 
maternal-lethal effect (Hersh et al., 2002). In such embryos, the increase in autophagy is 
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likely due to the onset of a starvation phenotype caused by a decrease in nutrient and 
biosynthetic compound availability (Schaheen et al., 2006). Suppression of the 
autophagic pathway partially relieves death in such mutant, suggesting that impaired 
lysosomal function strongly contributes to lethality (Sun et al., 2011, Schaheen et al., 
2006).  
More recently, studies performed in mammals have given important hints to the 
dissection of the molecular mechanisms behind the regulation of autophagy by TRPML1. 
Indeed, TRPML1 is a crucial factor in the activation of TFEB (Settembre et al., 2011, 
Sardiello et al., 2009). In nutrient rich condition TFEB is inactivated by mTORC1 mediated 
phosphorylation on two key serine residues (S142 and S211) and localises in the 
cytoplasm. Conversely, in conditions of nutrient starvation, mTORC1 is inhibited and TFEB 
is de-phosphorylated shuttling into the nucleus to activate the transcription of lysosomal 
and autophagy genes (Settembre et al., 2012). Starvation triggers the release of 
lysosomal Ca2+ through the activation of TRPML1 (Medina et al., 2015, Wang et al., 2015), 
Ca2+ activates the Ca2+-CaM-dependent Calcineurin (CaN) phosphatase, which in turn 
binds and de-phosphorylates S142 and S211 on TFEB (Medina et al., 2015). De-
phosphorylated TFEB enters into the nucleus to drive a transcriptional program to 
activate and sustain autophagy. Interestingly, TRPML1 is a transcriptional target of TFEB, 
therefore establishing a positive feedback loop which boosts TRPML1-TFEB response 
(Settembre et al., 2011, Medina et al., 2015, Wang et al., 2015). Depletion of TRPML1 or 
CaN impairs TFEB activation, demonstrating that the three proteins cooperate in a 
lysosome-to-nucleus signalling pathway to coordinate starvation-mediated autophagy 
(Medina et al., 2015).  
Of note, the over-expression of TRPML1 results in a significant increase of the autophagic 
flux, whereas its silencing reduces PI3P-positive vesicles and WIPI2 positive spots upon 
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starvation, raising the possibility that TRPML1 might also have some role in the early steps 
of autophagy (Medina et al., 2015). Intriguingly, nutrient starvation causes a decrease in 
levels of PI(3,5)P2, the only known endogenous agonist of the TRPML1 channel, raising 
the unresolved question of how nutrient deprivation controls TRPML1 channel activity 
(Zhang et al., 2012, Medina et al., 2015, Spooner et al., 2013, Zolov et al., 2012). Since 
TRPML1 channel activity is sensitive to pH, a potential explanation may be related to 
changes in the cytosolic pH during starvation (Li et al., 2016).  
Recently, a similar TRPML1/TFEB pathway has been described upon reactive oxygen 
species (ROS) production. In this case, TRPML1 acts as a sensor for ROS levels in the cell 
and becomes activated or sensitised upon high ROS condition, such as mitochondrial 
damage. TRPML1-mediated Ca2+ release from the lysosome stimulates CaN and activates 
TFEB transcription to promote autophagy and lysosomal biogenesis (Zhang et al., 2016). 
In a context in which TRPML1 function is abolished, such as MLIV, lysosomal Fe2+ 
accumulation could contribute to ROS production, which in turn provokes impairment of 
mitochondrial membrane potential and accumulation of damaged mitochondria which 
cannot be recycled because of the block of autophagy (Zhang et al., 2016, Coblentz et al., 
2014).  
Despite the emerging interest in the role of TRPML1 on autophagy, there are still many 
open questions about the precise role of this channel and of lysosomal calcium in this 
important catabolic process. Indeed, most of the studies in mammalian cells are limited 
to human fibroblasts or heterologous cell lines that have been depleted of TRPML1 by 
transient siRNA-silencing. Another important aspect that has not been addressed yet is 
whether the mTOR pathway alteration observed on invertebrate models such as C. 
elegans or Drosophila can be observed in mammalian cells. The use of new approaches 
such as CRISPR/Cas9 technology and human fibroblast reprogramming (such as induced 
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pluripotent stem cell, iPSCs) might contribute to the generation of better models to study 
TRPML1 function in specific cell types that are relevant in MLIV disease. Finally, a few 
lysosomal Ca2+ effectors involved in specific TRPML1 functions have been identified. 
Some examples are SytVII, CaN, and ALG-2 therefore it is likely that other TRPML1 
effectors and interactors, signalling cascades and molecular events modulating TRPML1 
will be identified in the next future. 
 
Figure 2: Scheme of the major TRPML1 functions. Lysosomal Ca2+ release by TRPML1 is important for the 
execution of different intracellular pathways. TRPML1 has been involved in the regulation of Ca2+-
dependent lysosomal exocytosis (top left). TRPML1 activity has been involved in vesicular fusion events and 
lysosomal re-formation (bottom left). Upon different environmental cues, such as nutrient deprivation, 
TRPML1 activation induces TFEB-mediated transcriptional program (top right). TRPML1 triggers in-ward 
lysosomal movement by a mechanism that requires ALG-2 and the Dynein-Dynactin complex (bottom 




Lysosomal calcium release trough TRPML1 regulates autophagy through 
calcineurin and TFEB 
Lysosomes are membrane-bound organelles present in all cell types. Their role in 
degradation and recycling processes has been extensively characterized (Luzio et al., 
2007, Saftig and Klumperman, 2009, de Duve, 2005). The acidic pH of the lysosomal 
lumen with the presence of a broad variety of hydrolases able to degrade an ample 
spectrum of substrates, makes these organelles extraordinary machineries for the 
recycling of cellular waste. Extracellular substrates reach the lysosome mainly via the 
endocytic and phagocytic pathways, while intracellular substrates are the delivered to 
the lysosome by the autophagic pathway via the fusion of autophagosomes with 
lysosomes (Luzio et al., 2007, Saftig and Klumperman, 2009). Thus, lysosomes are the 
“terminal end” of most cellular catabolic pathways. The role of the lysosomes in 
degradation and recycling processes has always been considered as a cellular 
“housekeeping” function and little attention has been paid to the regulation of these 
processes and to the influence of environmental cues, such as starvation and physical 
exercise. 
The discovery that the Transcription Factor EB (TFEB) is a master regulator of lysosomal 
and autophagic function and of energy metabolism (de Duve, 2005, Saftig and 
Klumperman, 2009, Luzio et al., 2007) suggested that environmental cues may control 
lysosomal function via the induction of a broad transcriptional program. TFEB activity is 
regulated by phosphorylation (He and Klionsky, 2009, Luzio et al., 2009, de Duve, 2005, 
Saftig and Klumperman, 2009, Luzio et al., 2007), which keeps TFEB inactive in the 
cytoplasm, while de-phosphorylated TFEB travels to the nucleus to activate 
transcriptional target genes. TFEB phosphorylation is mediated by mTORC1, a major 
kinase complex that positively regulates cell growth and negatively regulates autophagy. 
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Interestingly, it is known mTORC1 exerts its activity on the lysosomal surface and is 
positively regulated by lysosomal nutrients (Sardiello et al., 2009, Settembre et al., 2011). 
The regulation of TFEB by lysosomal mTORC1 and the shuttling of TFEB to the nucleus 
revealed a lysosome-to-nucleus signalling mechanism (de Duve, 2005). Thus, these 
studies identify the lysosome as a signalling hub controlling cellular homeostasis via both 
post-translational and transcriptional mechanisms (He and Klionsky, 2009, de Duve, 2005, 
Saftig and Klumperman, 2009, Luzio et al., 2007).  
An important aspect emphasised in this chapter is the classification of the lysosome, not 
only as the terminal end of all the material that needs to be degraded, but as calcium 
storage organelle that actively participate to calcium signalling processes. Calcium ions 
are important second messengers that are involved in several biological processes. Rapid 
and highly localised Ca2+ spikes regulate membrane fusion (Berridge et al., 2003), cellular 
motility and could regulate enzyme activity, permeability of ion channels (Ali et al., 2016), 
activity of ion pumps, and components of the cytoskeleton. To execute their function Ca2+ 
ions should diffuse through the cytoplasm and since this diffusion is not energetically 
favoured in a cytoplasm crowded of organelles there are many calcium binding proteins 
that amplify the calcium wave signal (Clapham, 2007). Furthermore, endoplasmic 
reticulum and mitochondria, which represent the major calcium storage in the cytoplasm, 
are widely spread in the cytoplasm providing a calcium source in the whole cell. This 
underlies how calcium signalling requires proximity and rapidity, a valid example is given 
by the sarcoplasmic reticulum in the skeletal muscles providing Ca2+ to the adjacent 
muscle proteins in an efficient and rapid manner (Clapham, 2007). Equally, lysosome 
could store Ca2+ and participate to calcium signalling processes. Several calcium channels 
reside on the lysosomal membrane. Recent studies have investigated the role of these 
lysosomal calcium channels in fundamental cellular processes and their involvement in 
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disease mechanisms (Morgan et al., 2011). One of the major channels on the lysosome is 
represented by MCOLN1, a non-selective cation channel which releases Ca2+ from the 
lysosomal lumen into the cytoplasm.  In this chapter the mechanism by which the release 
of calcium via MCOLN1, leads to calcium increase in the proximity of the lysosomes 
triggering autophagy via calcineurin-mediated induction of TFEB will be discussed. 
Starvation induces lysosomal Ca2+via TRPML1 
Since starvation-induced TFEB nuclear translocation requires the activity of calcineurin 
and the subcellular localisation of TFEB is calcium mediated, the effect of starvation on 
cytosolic Ca2+was evaluated in collaboration with Dr. De Stefani and Dr. Rizzuto 
(affiliation). The overall levels of cytosolic Ca2+were measured by an aquaporin-based 
probe localising in the bulk cytoplasm which remained unaltered during starvation (Fig. 3 
a). Moreover, while a fast calcium chelator, like BAPTA-AM, was able to reduce 
starvation-mediated TFEB nuclear translocation, a slower calcium chelator, like EGTA-AM 
(Morgan et al., 2013), did not (Fig. 3 b). To address this point the release of calcium from 
the endoplasmic reticulum (ER) was quantified by measuring cytosolic calcium transiently 
evoked by the IP3-mobilising hormone histamine in fed and starved cells (Fig. 3 a,c). To 
specifically measure the lysosomal calcium release a plasmid developed in Dr. Xu’s 
laboratory was used (Samie et al., 2013). This plasmid called ML1-GCaMP3 allows the 
expression of the calcium channel TRPML1 fused with GFP protein, which thanks to a 
calmodulin binding domain, is sensitive to calcium ions (Samie et al., 2013). The GFP 
fluorescence is quenched in basal condition but once Ca2+ is released by TRPML1 the 
calmodulin domain allows structural changes in the GFP which becomes able to emit 
green fluorescence. HeLa cells transiently transfected with this construct clearly showed 
that starvation is able to release calcium from TRPML1 (Fig. 3 d). The same was observed 
in HEK293 cells stably overexpressing ML1-GCaMP3 (Fig. 3 e). The increase in Ca2+ levels 
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induced by starvation detected by ML1-GCaMP3 were not affected by the removal of 
extracellular Ca2+ (ruling out the contribution of plasma membrane calcium channels), 
but was blunted by treatment with the lysosomotropic agent GPN (Fig. 3 f).  
 
Figure 3: Starvation induces lysosomal Ca2+ release through MCOLN1. (a) Starvation does not induce bulk 
cytosolic Ca2+ elevation in HeLa cells transfected with the Ca2+-sensitive probe aequorin. Bulk cytosolic 
[Ca2+] was monitored during perfusion with complete L-15 medium, HBSS and HBSS supplemented with 
100µM histamine as indicated. (b) Stable HeLa TFEB–GFP cells were left untreated or pre-treated for 30min 
with the Ca2+ chelators BAPTA-AM or EGTA-AM (5µM each). After washing, cells were left untreated or 
starved for 1h. After treatment, cells were fixed and a high-content imaging analysis was performed. The 
plot shows the percentage of TFEB nuclear translocation in BAPTA-treated cells compared with untreated 
and EGTA treated. (c) Average and s.d. of cytoplasmic [Ca2+] evoked by maximal histamine stimulation in 
wild-type HeLa cells. Agonist stimulation was carried out in complete L15 medium or after a three-minute 
starvation with HBSS. (d) Representative traces of the cytosolic GCaMP6s and the perilysosomal ML1-
GCaMP3 calcium probes. HeLa cells were transfected with the indicated probe and ratiometric imaging 
(474 and 410nm excitation) was performed. Cells were continuously perfused with the indicated solutions. 
The bottom left plot represents the average perilysosomal calcium peak values induced by perfusion of the 
indicated buffer, as recorded by the GCaMP3–ML1 probe. The bottom right plot represents the average 
cytosolic calcium peak values induced by perfusion of the indicated buffer, as recorded by the GCaMP6s 
probe. (e) Ca2+ release (measured with 1F/F0 fluorescence intensity) was detected right after the L-15 
medium (containing 2mM [Ca2+], amino acids and 10% FBS) was switched to Tyrode’s solution (2mM [Ca2+]) 
in HEK293 cells stably expressing GCaMP3–ML1. The agonist of MCOLN1 ML-SA1 (10µM) was applied to 
induce MCOLN1-mediated Ca2+ release. (f) Similarly, the lysosomotropic drug GPN blunted starvation-





Moreover, neither the silencing of the lysosomal two-pore channel TPCN2 nor the 
overexpression of a critical regulator of mitochondrial Ca2+ uptake, MICU1 altered TFEB 
subcellular localisation (Fig. 4 a, b). These data clearly demonstrate that during starvation the 
lysosomes, via TRPML1, release calcium generating a local calcium spike responsible of PPP3CB 
activation. Successively, the involvement of TRPML1 in the modulation of TFEB nuclear 
translocation was assessed (Dong et al., 2010, Shen et al., 2012, Samie et al., 2013, Medina et 
al., 2011).  
 
Figure 4: TPCN2 and MICU1 calcium channels do not regulate TFEB localisation. (a) Depletion of the 
lysosomal two-pore channel TPCN2 does not affect TFEB nuclear translocation during starvation (1 hour) 
(left graph). Quantification of the efficiency of TPCN2 gene silencing by qPCR analysis (right graph). (b) 
Overexpression of the essential mitochondrial Ca2+ regulator MICU1 does not impact on the subcellular 
localisation of TFEB in fed and starvation conditions (1hr), as compared to untransfected cells. High content 
imaging analysis was used to quantify TFEB localisation using HeLa-TFEB-GFP cells. 
 
A significant reduction in nuclear localisation during starvation of TFEB both overexpressed and 
endogenous was observed by using a cell line stably transfected with a short hairpin RNA 
(shRNA) targeting TRPML1. (Fig. 5 a). This endorsed consistently that this process requires 
lysosomal calcium release. Similar results were obtained by nucleus/cytoplasm fractionation 
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(Fig. 5 b). Consistently, depletion of TRPML1 reduced the downshift of endogenous TFEB 
molecular weight during starvation, suggesting a defective de-phosphorylation (Fig. 5 d). 
Mutations in the TRPML1 gene cause Mucolipidosis type 4 (MLIV), a lysosomal storage 
disease (Bassi et al., 2000, Bargal et al., 2000). Starvation-induced nuclear translocation 
of TFEB is inhibited in fibroblasts from MLIV patients (Fig. 5 c).  
 
Figure 5: MCOLN1-mediated calcium release induces TFEB nuclear translocation. (a, b) Silencing of 
MCOLN1 reduces starvation-mediated TFEB nuclear translocation. (a) HeLa cells or a HeLa cell line stably-
transfected with a MCOLN1 shRNA was left untreated or transiently transfected with a TFEB–GFP plasmid. 
The left plot shows the percentage of TFEB–GFP nuclear translocation in starved (3h) HeLa-MCOLN1 shRNA 
cells compared with starved HeLa cells. Similarly, the middle plot shows the results on endogenous TFEB 
nuclear translocation. The right plot shows the efficiency of MCOLN1 silencing. (b) Silencing of MCOLN1 
reduces starvation-mediated TFEB nuclear translocation. HeLa and HeLa-MCOLN1 shRNA cells were 
transfected with a TFEB–3×FLAG construct. Following starvation, of 100µg nuclear and 50µg of cytosolic 
extracts were prepared and probed using anti-Flag antibody. (c) Endogenous TFEB nuclear translocation 
analysis of human wild-type and mucolipidosis IV fibroblasts in fed conditions and after a 3h starvation of 
serum and amino acids. The graph shows the percentage of TFEB nuclear translocation in human MLIV cells 
when compared with WT cells in starvation conditions. (d) Depletion of the lysosomal calcium channel 
MCOLN1 reduces starvation mediated TFEB nuclear translocation. WT HeLa and HeLa-shMCOLN1 cells 
were starved at different time-points. Following starvation, 50µg of protein extracts were prepared and 
probed for endogenous TFEB using anti-TFEB antibodies. TFEB mobility downshift after starvation is 
reduced in MCOLN1 depleted cells during starvation (black arrows point-out the phosphorylated forms, 





On the other hand, overexpression of TRPML1 and of gain of function mutants (GOFs) in 
HeLa TFEB-GFP promotes TFEB nuclear translocation (Fig. 6 a) in a calcineurin dependent 
fashion (Fig. 6 b). Furthermore, similar results were obtained using a TRPML1 specific 
agonist, SF-51 (Shen et al., 2012) (Fig. 6 c, d). 
 
Figure 6: MCOLN1-mediated calcium release induces TFEB nuclear translocation. (a) Overexpression of 
MCOLN1 induces TFEB nuclear translocation. HeLa cells stably expressing TFEB–GFP were transfected with 
plasmids carrying wild-type or constitutively active mutant forms of FLAG-tagged MCOLN1. TFEB 
subcellular localisation was assessed in FLAG-positive (red-stained cells) and negative cell populations. The 
graph shows the percentage of TFEB nuclear translocation in the different GOF mutation carrying cells, 
compared with non-transfected cells. (b) MCOLN1-mediated induction of TFEB nuclear localisation is 
calcineurin-dependent. HeLa TFEB-GFP cells were transfected with FLAG-tagged MCOLN1 gene in 
combination with siRNAs against PPP3CB and PPP3R1 (siCaN) or scramble siRNA oligonucleotides 
(SCRMBL). TFEB subcellular localisation was assessed in FLAG-positive population using HC imaging. The 
graph shows the percentage of nuclear TFEB in siCaN knock-down cells compared with control SCRMBL-
transfected cells. (c) Frames of time-lapse experiments in HeLa TFEB–GFP cells treated with the MCOLN1 
agonist SF-51 (200µM) after the transfection of PPP3CB+PPP3R1 (CaN) siRNA, MCOLN1 or scramble siRNAs. 
Yellow arrowheads indicate TFEB nuclear localization. The plot shows the kinetics of TFEB nuclear 
localisation during the time of recording. (d) The MCOLN1 agonist SF-51 induces TFEB nuclear 
translocation. The effect of SF-51 treatment on HeLa TFEB-GFP cells at the time points indicated in the plot 
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was quantified using an HC assay. The graph shows the percentage of treated cells with nuclear TFEB 
compared to DMSO control cells. 
 
Since TRPML1 and the release of lysosomal calcium are required for calcineurin activation, 
whether also the silencing of TRPML1 generate the same autophagy impairment was 
investigated. Consistently with previous data, the silencing of TRPML1 significantly reduced the 
number of PI(3)P-positive vesicles as measured by the GFP–2×FYVE reporter (Fig. 7 a). 
Conversely, overexpression of TRPML1 significantly increased the level of the autophagosome 
marker LC3, and co-treatment with bafilomycin A1 led to a further increase, indicating an 
induction of autophagy, rather than an impairment of autophagosome degradation (Fig. 7 b, c). 
Thus, lysosomal calcium signalling via MCOLN1 controls autophagy through calcineurin-
mediated activation of TFEB. Intriguingly, TRPML1 is a direct transcription target of TFEB 
(Medina et al., 2011, Palmieri et al., 2011). This suggests the existence of a positive feedback 
loop by which TFEB regulates the expression of TRPML1, which in turn promotes TFEB activity 




Figure 7: MCOLN1 regulates the lysosomal/autophagic pathway. (a) Representative images and analysis 
of the overexpression of the autophagy related PI(3)P reporter GFP–2×FYVE during starvation in wildtype 
(Mock) HeLa cells, and in cells silenced for MCOLN1. GFP–2×FYVEpositive vesicles (in green) were counted 
using ImageJ software. (b) MCOLN1 overexpression leads to a significant increase in LC3 levels. HeLa cells 
were transfected with Myc-tagged MCOLN1 or gain-of-function mutants R427P and V432P respectively. 
Immunofluorescence was performed using antiLC3 antibodies. The number of LC3 spots per cell was 
quantified using high-content imaging analysis. (c) Fifty micrograms of protein extracts from HeLa cells 
treated with bafilomycin (BAFA) and overexpressing an empty vector of a Myc–MCOLN1 plasmid for 24h 
was immunoblotted against LC3.  
 
Autophagy is an evolutionary conserved mechanism by which cells degrade and recycle 
self-components in order to maintain cellular homeostasis (Mizushima et al., 2008). This 
degradative lysosomal pathway is tightly regulated and the nutritional stress is 
considered the major stimulus triggering it (Lum et al., 2005, Onodera and Ohsumi, 2005). 
Due to its relevance, regulation of autophagy is thought to be a biphasic process, with a 
fast induction which relies on post-translational and protein-protein interaction events, 
and a sustained response which is mediated by transcriptional mechanisms (Fullgrabe et 
al., 2014). In this chapter, the mechanism by which a calcium release via TRPML1 from 
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lysosome could regulate autophagy by activating a TFEB-mediated transcriptional 
program has been described. Although it has been well-established that autophagy is 
negatively regulated by the mTOR kinase (Yang and Klionsky, 2010) the pathway 
identified in the present study is mediated by the Ca2+-dependent phosphatase 
calcineurin and seems to operate independently from mTOR.  The results discussed in 
this chapter allow to delineate a working model of how starvation and exercise regulate 
TFEB via both the mTOR and calcineurin pathways (Fig. 8). In basal feeding/sedentary 
conditions mTORC1 phosphorylates TFEB allowing its interaction with 14-3-3 proteins, 
thus preventing its nuclear translocation. Conversely, during starvation and physical 
exercise mTORC1 activity is inhibited and, at the same time, calcineurin activity is locally 
induced by lysosomal calcium release via MCOLN1. This leads to both a decreased rate of 
TFEB phosphorylation, via mTORC1 inhibition, and an induction of TFEB de-
phosphorylation, via calcineurin induction. De-phosphorylated TFEB is free to travel to 
the nucleus and to induce the expression of lysosomal and autophagic genes (Fig. 8). 
 
 
Figure 8: Model of Ca2+ mediated regulation of TFEB. Under feeding conditions TFEB is phosphorylated on 
the lysosomal surface and is sequestered in the cytoplasm by the 14-3-3 proteins. During starvation and 
physical exercise Ca2+ is released from the lysosome via MCOLN1, thus establishing a Ca2+ microdomain. 
This leads to calcineurin activation and TFEB de-phosphorylation. De-phosphorylated TFEB is no longer able 




Previous studies reported that exercise induces autophagy in muscle (He et al., 2012, 
Grumati et al., 2011, Jamart et al., 2013). The results described in this chapter provide a 
mechanistic link between calcineurin activation and autophagy induction during exercise. 
To date, the transcription factors of the NFAT family, master regulators of T cell activation 
(Macian, 2005), have been considered the main transcriptional mediators of calcineurin 
function. The discovery that TFEB, a master controller of autophagy, is a calcineurin 
substrate expands the current view on the mechanism of action of calcineurin. 
Interestingly, starvation induces calcineurin-mediated de-phosphorylation and nuclear 
translocation of both TFEB and NFAT, suggesting a coordinated regulation of the two 
different transcriptional networks. Previous studies implicated calcineurin in a variety of 
both physiological and pathological processes, such as neuronal synaptic transmission, 
adaptive immune response and muscle remodelling after physical exercise (Rusnak and 
Mertz, 2000, Kasahara et al., 2013). The data reported here suggest that some of these 
processes may be linked to the lysosomal/autophagic pathway via TFEB. In addition, 
other calcineurin substrates may also play a role in autophagy. 
Calcium is considered a key regulator of the autophagy pathway, its availability and 
distribution inside storage compartment and cytoplasm is critical for autophagy 
regulation. A key role is fulfilled by calcium storage organelles, endoplasmic reticulum 
(with a Ca2+ concentration of about 0.4 – 0.8mM), mitochondria (with a Ca2+ 
concentration of about 200nM) and lysosome (with a Ca2+ concentration of about 0.4 – 
0.6mM) (Christensen et al., 2002, Shigetomi et al., 2016), even if, more than the storage 
organelles per se, there are fundamental players located in those compartment that 
dynamically control the release of calcium to the cytosol and vice versa (Filippi-Chiela et 
al., 2016). Indeed, the inositol 1,4,5 – triphosphate receptor (IP3-R) is located on the 
endoplasmic reticulum (Berridge, 2009), the voltage dependent anion channel (VDAC1) 
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and the mitochondria calcium uniporter regulator 1 (MCUR1) are found on the 
mitochondrial outer and on  inner membrane respectively (Williams et al., 2013), while 
on the lysosome there are TRPML1 and 3 (Christensen et al., 2002). IP3-R is the main Ca2+ 
effector, it links environmental signals to autophagy since its ligand IP3 increases in 
response to ATP, hypoxia, hormones, growth factors and neurotransmitters (Berridge, 
2009). On the other hand, VDAC1, is involved together with IP3-R, in calcium transfer 
from endoplasmic reticulum to mitochondria. Calcium storage inside mitochondrial 
lumen is fundamental for Krebs cycle and ATP production, thus impairment in this calcium 
transfer leads to mitochondrial malfunction and autophagy (Mallilankaraman et al., 2012, 
Williams et al., 2013). In addition, regarding lysosome in this chapter we have dissected 
a Ca2+-dependent pathway that thanks to calcium release, via MCOLN1, regulates 
autophagy at the transcriptional level. Our study demonstrates that local calcineurin 
activation near the lysosome occur due to the calcium microdomain generated by the 
calcium release of MCOLN1. In addition, our data also revealed a positive feedback loop 
by which the TFEB is activated by the calcium channel MCOLN1, which is known to be a 
TFEB transcriptional target (Palmieri et al., 2011). 
In conclusion, the identification of a mechanism by which lysosomal Ca2+ regulates 
autophagy via MCOLN1 and the activation of the transcription factor TFEB by calcineurin 
further support the role for the lysosome as a signalling hub. It is likely that future studies 
will lead to the identification of other signalling pathways originating from the lysosomal 
surface. 
TRPML2 and TRPML3  
Other than TRPML1, the TRPMLs subfamily is made of other 2 members, TRPML2 and 
TRPML3. TRPML2 mRNA is expressed in high levels in thymus, spleen, lymphatic nodes 
and kidney (Samie et al., 2009, Grimm et al., 2010, Sun et al., 2015). Interestingly, 
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transcript levels of TRPML2 co-vary with those of TRPML1. Indeed, in lymphoid tissues 
and primary cells from mouse or human cell models, TRPML2 transcript levels is 
significantly reduced in the absence of TRPML1 and increased upon TRPML1 over-
expression or stimulation by specific activators or nicotinic acid adenine dinucleotide 
phosphate (NAADP).  This suggests a regulatory role for TRPML1 in the expression and 
function of TRPML2 in these specialised tissues (Samie et al., 2009). Different studies 
using over-expressed TRPML2 reported the localisation of the protein to the lysosomes 
and partially to the plasma membrane (demonstrated by whole cell current recording) 
(Venkatachalam et al., 2006, Zeevi et al., 2009, Song et al., 2006). Moreover, TRPML2 has 
been also found to localise onto tubular recycling endosomes, where it is associated with 
the ARF6-dependent pathway (Karacsonyi et al., 2007). In activated macrophages and 
microglia, intracellular distribution of the endogenous TRPML2 protein is almost 
exclusively present in recycling endosomes (Sun et al., 2015). By using a GOF mutant 
(TRPML2Va; A369P), which carries the same constitutively active Varitint-Waddler 
mutation described for TRPML3 (see below), it has been demonstrated that TRPML2 is a 
non-selective Ca2+-, Na2+- and Fe2+-permeable channel. Like other mucolipin family 
members, TRPML2 can generate inwardly rectifying current, thus transporting cations 
from the lumen of endosomes, lysosomes or extracellular space to the cytosol (Dong et 
al., 2008, Grimm et al., 2012, Grimm et al., 2007). Wild-type TRPML2 single channel 
current has been only measured in synthetic membrane bilayers containing translated 
TRPML2 produced in vitro or in mammalian cells. TRPML2 shows limited single channel 
conductance, although the in vitro approach used to perform the measurements may 
underestimate the effective conductance of the channel (Curcio-Morelli et al., 2010b). 
TRPML2 can interact with the other two members of the family to form dimers, although 
these interactions are present to a very limited extent (Venkatachalam et al., 2006, Zeevi 
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et al., 2009). Hetero-dimerization of over-expressed wild type or dominant negative 
TRPML2 with TRPML1 and TRPML3 gives rise to channel complexes with altered 
conductance, suggesting that these interactions may be physiologically relevant for the 
regulation of TRPMLs channel activity upon specific conditions (Curcio-Morelli et al., 
2010b, Zeevi et al., 2010). As described for TRPML1, activity of TRPML2 channel can be 
physiologically stimulated by both protons and PI(3,5)P2 (Dong et al., 2008, Dong et al., 
2010, Lev et al., 2010). In addition to endogenous stimuli, three synthetic compounds, 
named SF-21, SF-41 and SF-81 (Table 1), have been characterized as activators of both 
wild type TRPML2 and TRPML3 (Grimm et al., 2010, Grimm et al., 2012). These molecules 
may be of particular interest in the development of therapeutic strategies to treat MLIV, 
caused by loss-of-function mutation in the TRPML1 gene. Thus, the activation of potential 
and functional redundant TRPMLs may mitigate the symptoms of MLIV disease. Unlike 
TRPML1, no monogenic diseases correlated with TRPML2 loss-of-function have been 
identified so far. Interestingly, the enrichment of TRPML2 transcript in lymphoid tissues, 
like spleen and thymus, and immune cells, such as B-cell lines and primary B-lymphocytes, 
raised the hypothesis of a regulatory role of TRPML2 in the immune system (Samie et al., 
2009, Grimm et al., 2010, Sun et al., 2015, Lindvall et al., 2004). TRPML2 has been found 
significantly down-regulated in B-cells lacking the Bruton Tyrosine Kinase (BTK), a kinase 
involved in B-lymphocyte development, thus suggesting a role of BTK signalling cascade 
in the regulation of TRPML2 expression (Lindvall et al., 2004, Lindvall et al., 2005). 
Furthermore, it has been shown that the transcription factor PAX5, also known as B-cell 
specific activator protein (BSAP), controls the expression of TRPML2 gene (Valadez and 
Cuajungco, 2015). Finally, TRPML2 is a molecular partner of the plasma membrane 
protein TMEM176A, which negatively regulates the maturation and activation of 
dendritic cells (Chen et al., 2014). Interestingly, a role for TRPML2 on innate immune 
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response has also been recently described. Indeed, TRPML2 is present at very low levels 
in resting macrophages, but its expression dramatically increases in response to TLRs 
activation, whereas the mRNA levels of TRPML1 and TRPML3 do not change during similar 
stimuli (Sun et al., 2015). Furthermore, by generating a knockout mouse model, it has 
been assessed that the absence of TRPML2 reduces chemokine release from bone 
marrow-derived macrophages (BMDMs) and, subsequently, their ability to migrate. 
Altogether these evidences strongly suggest a specific role for TRPML2 in immune 
response, although further investigations are needed to clarify the mechanism of TRPML2 
activation, such as the identification of the physiological events activating TRPML2 
expression and function, likely via BTK and PAX5, and its possible role in the 
internalisation and recycling of plasma membrane proteins acting as immune receptors.  
Similarly to TRPML1 and TRPML2, TRPML3 is an inwardly rectifying non-selective cation 
channel. TRPML3 was primarily identified as the gene carrying the causative mutation of 
the Varitint-Waddler (Va) phenotype in mice. The typical Va mutation affects hair cells of 
the cochlea causing severe stereocilia disorganisation in both the inner and outer hair 
cells (Di Palma et al., 2002). Va mutant mice suffer early-onset hearing loss, vestibular 
defects, pigmentation abnormalities and perinatal lethality. The mutated TRPML3 gene 
can produce two semi-dominant alleles: Va and VaJ. The Va allele is responsible for the 
most severe phenotype and is the result of the Ala to Pro substitution that occurs at the 
position 419 (A419P) located on the fifth transmembrane domain of TRPML3. In the VaJ 
mutant a second sequence alteration (I362T) occurring in cis partially rescues the Va 
allele. Va/Va mice are severely affected and exhibit multiple symptoms and reduced 
viability. +/VaJ mice show the mildest phenotype, are viable, display only limited 
variegation and coat colour dilution and have some residual hearing. VaJ/VaJ and +/Va 
mice show intermediate and similar phenotypes (Di Palma et al., 2002).  
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Studies performed on the TRPML3 channel properties have shown that the mutation 
occurring in the Va mutant mice (A419P) results in the constitutive activation of the 
channel (Xu et al., 2007, Grimm et al., 2007, Nagata et al., 2008, Kim et al., 2007),more 
precisely, introduction of a proline substitution in  positions 413 to 419 of the fifth 
transmembrane domain causes helix-breaking which leads to channel activation. The 
generation of a TRPML3 GOF on the plasma membrane leads to massive Ca2+ overload, 
membrane depolarisation and subsequent cell death by apoptosis (Xu et al., 2007, Grimm 
et al., 2007, Nagata et al., 2008, Kim et al., 2007). The presence of a second mutation 
(I362T) in the VaJ allele attenuates current density and reduces protein localisation at the 
plasma membrane, resulting in a milder phenotype (Grimm et al., 2007, Kim et al., 2007).  
Endogenously expressed TRPML3 mRNA and protein have been found in the inner ear of 
wild type mice (Di Palma et al., 2002, Nagata et al., 2008). In HEK293 and CL4 cellular 
models, over-expressed TRPML3 localises on cytosolic vesicular structures and plasma 
membrane (Xu et al., 2007, Venkatachalam et al., 2006, Di Palma et al., 2002, Nagata et 
al., 2008). In ARPE19 cells, these structures were identified as early and late endosomes 
(Martina et al., 2009). The silencing of TRPML3 accelerates endocytosis of EGF and 
transferrin, whereas TRPML3 over-expression results in the opposite effect (Kim et al., 
2009). TRPML3 has also been linked to the autophagy pathway (Kim et al., 2009). Indeed, 
upon starvation, the over-expression of the channel stimulates formation of 
autophagosomes, with a strong co-localisation of TRPML3 protein within these structures 
(Kim et al., 2009). Interestingly, TRPML3 specifically binds to GATE16, a mammalian ATG8 
homolog important for autophagosome maturation (Choi and Kim, 2014). However, the 
link between TRPML3, GATE16 and autophagosome maturation, as well as the relevance 
of TRPML3 in autophagy has not yet been fully clarified. Finally, a novel function for 
TRPML3 in the neutralisation of bacterial infection has been recently described. In 
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particular, TRPML3 acts as a pH sensor during bacterial internalisation promoting 
lysosomal exocytosis to clear bacteria and therefore re-establishes proper lysosomal 
function (Miao et al., 2015). 
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Table 1 : List of endogenous and synthetic modulators of TRPML channels activity. Modified with permission 
from: Di Paola et al. (Di Paola et al., 2017) 











Activator (Grimm et al., 2010, Shen et al., 2012) 
MK6-83 TRPML1, TRPML3 Activator (Chen et al., 2014) 
SF-22; SF-51 TRPML1, TRPML3 Activator 
(Grimm et al., 2010, 
Shen et al., 2012) 
SF-21; SF-41, SF-81 TRPML2, TRPML3 Activator 
(Grimm et al., 
2012) 
Na+ TRPML2 Activator (Grimm et al., 2012) 
SF-11; SN-1; SN-2 TRPML3 Activator (Grimm et al., 2010) 
SF-23; SF-24; SF-31; SF-32; SF-33; 
SF-61; SF-71 TRPML3 Activator 
(Grimm et al., 
2010) 
ML268; ML269 TRPML3 Activator (Saldanha et al., 2010) 
Sphingomyelins TRPML1 Inhibitor (Shen et al., 2012) 
phosphatidylinositol (4,5) 
bisphosphate (PI(4,5)P2) TRPML1 Inhibitor (Zhang et al., 2012) 
Verapamil TRPML1, TRPML3 Inhibitor (Xu et al., 2007) 
La3+ TRPML1 Inhibitor (Dong et al., 2010) 
Na+ TRPML3 Inhibitor (Grimm et al., 2012, Kim et al., 2007) 











TRPML1 links lysosomal calcium to autophagy initiation 
Abstract 
TRPML1 (or Mucolipin 1) is a cation-permeable channel localized on the membranes of 
late endosomes and lysosomes (LELs) of mammalian cells. TRPML1 has been involved in 
vesicular trafficking, vesicular fusion, phagocytosis of large particles, and lysosomal 
exocytosis (Medina et al., 2011, Samie et al., 2013, Manzoni et al., 2004, Di Paola et al., 
2017). We have recently shown that lysosomal Ca2+ release, through TRPML1, plays a 
major role in lysosomal adaptation to starvation by inducing calcineurin that de-
phosphorylates and activates TFEB, a master gene of lysosomal function (Medina et al., 
2015). While studying the role of TRPML1 in autophagy, we also observed that the 
inhibition of TRPML1 significantly reduced the recruitment of the WD-repeat PtdIns(3)P 
effector  protein WIPI2 to vesicles. Since WIPI2 is an essential effector at the nascent 
autophagosome (Mauthe et al., 2011), we reasoned that the activity of the lysosomal 
calcium channel TRPML1 may play a role in autophagosome biogenesis. Indeed, we found 
that TRPML1-activation induces the recruitment of PtdIns(3)P-binding proteins to the 
nascent autophagosome, whereas genetic or pharmacological inhibition of TRPML1 
channel inhibits autophagy initiation. Importantly, alteration of this novel identified 
function may be involved in the pathology of LSDs since we found that autophagosome 
formation is impaired in human fibroblasts from patients affected of mucolipidosis IV 
(MLIV; a severe LSD caused by mutations in TRPML1). We also found that WIPI2 puncta 
formation was closely to lysosomes overexpressing TRPML1-GFP suggesting that 
PtdIns(3)P nucleation occurs in the vicinity of TRPML1 activation. By silencing VAPs 
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proteins, that have been involved in the formation of numerous different membrane 
contact sites, we consistently reduced TRPML1-mediated induction of WIPI2 puncta 
formation upon agonist treatment. In addition, by using specific compound inhibitors 
during starvation, we found that TRPML1-mediated induction of autophagosome 
biogenesis requires calmodulin, CaMKKβ, and the PtdIns(3)-generating enzyme PIK3C3 
(also called VPS34). Therefore, we propose a new lysosomal calcium signalling that 
through the activation of TRPML1 induces autophagosome biogenesis via the 
CaMKKβ/AMPK pathway, and the induction of two essential protein complexes involved 
in autophagy initiation the ULK1 and PIK3C3 complexes. 
Introduction 
Ca2+ is an universal second messenger that plays a fundamental role in cellular physiology 
regulating processes such as gene transcription, cell proliferation, migration and death 
(Berridge et al., 2000). By definition Ca2+ levels are extremely low in resting cells to allow 
a rapid release upon specific stimulus. Thus, the variety of cellular processes modulated 
by changes in Ca2+ concentration requires an exquisitely control of its intracellular levels 
to create a wide range of spatial and temporal signals (Berridge et al., 2000). An important 
manner to regulate Ca2+ is through the generation of gradients by intracellular Ca2+ 
stores, of which the endoplasmic reticulum (ER) is the major Ca2+ store organelle in the 
cell. Such compartmentalization allows the rapid mobilization of Ca2+ by the regulation of 
the expression and activity of Ca2+ permeable channels and thereby the modulation of 
Ca2+-dependent processes, such as cell proliferation, ER stress, and apoptosis (La Rovere 
et al., 2016). In addition, in the last years evidence is accumulating for a role of 
intracellular Ca2+ in autophagy (Decuypere et al., 2011b, Cardenas and Foskett, 2012, Yao 
and Klionsky, 2015, Medina et al., 2015, Medina et al., 2011). 
The role of Ca2+ in autophagy started to emerge in the early 90s, in which a first study 
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revealed that chelation of Ca2+ as well as the elevation of cytosolic Ca2+ suppressed 
autophagy (Gordon et al., 1993). This controversy has continued with the publication of 
many different studies supporting both positive and negative effects of Ca2+ on 
autophagy activation (Cardenas et al., 2010, East and Campanella, 2013, Decuypere et 
al., 2011a, Su et al., 2013, Gastaldello et al., 2010, Smaili et al., 2013). Thus, we are still 
far away to fully understand the precise mechanisms by which Ca2+ controls this 
important catabolic process, and how these mechanisms are integrated in well-known 
triggers/regulators of autophagy initiation such as nutrient deprivation, low cellular 
energy levels, ER stress, hypoxia and oxidative stress (Kroemer et al., 2010). 
Recently, lysosomal organelles are emerging as intracellular Ca2+ stores that play major 
roles in vesicular trafficking and autophagy. Most importantly, impairment of lysosomal 
Ca2+ homeostasis has been implicated in many human diseases such as lysosomal storage 
diseases (Morgan et al., 2011, Shen et al., 2012, Lloyd-Evans et al., 2008), 
neurodegeneration (Funk and Kuret, 2012, Bae et al., 2014, Ezeani and Omabe, 2016), 
muscular dystrophy, and cancer (Cheng et al., 2014, Kondratskyi et al., 2013, Galluzzi et 
al., 2015). The non-selective cation channel TRPML1 is the major calcium-release channel 
on the lysosomal membrane. TRPML1 activity has been involved in a variety of membrane 
trafficking processes such as endocytosis, exocytosis, phagocytosis and autophagy (Xu 
and Ren, 2015). In addition, mutations in the TRPML1 gene cause mucolipidosis type IV 
(MLIV: OMIN 252650), an autosomal recessive lysosomal disease characterized by 
psychomotor alterations, corneal opacities, and achlorhydia (Frei et al., 1998, Bargal et 
al., 2000). At the cellular level, both human fibroblasts affected of MLIV and TRPML1-/- 
neurons from a MLIV mouse model present autophagy impairment characterized by the 
accumulation of autophagic markers such as LC3 and p62 (Vergarajauregui et al., 2008b, 
Curcio-Morelli et al., 2010a). This phenotype is not exclusive of MLIV, and many other 
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LSDs present defects in autophagy that have been mainly explained as a consequence of 
global lysosomal dysfunction and/or defects of autophagosome-lysosome fusion. 
However, recent evidences strongly suggest that TRPML1 activity plays a direct role in 
the activation of autophagy. Thus, we have shown that lysosomal Ca2+ signalling regulates 
autophagy through calcineurin and its substrate TFEB (Medina et al., 2015). Lysosomal 
Ca2+ release through TRPML1 stimulates the calcium-dependent phosphatase calcineurin 
which binds and dephosphorylates its substrate TFEB, and thereby promoting its nuclear 
translocation to initiate the transcription of lysosomal and autophagic genes (Medina et 
al., 2015). In addition, we also observed that acute TRPML1 depletion reduces the 
formation of autophagosomes by using the PtdIns(3)P-binding reporter GFP-2xFYVE 
(Medina et al., 2015), suggesting a potential role of TRPML1-mediated lysosomal calcium 
release on the early steps of phagophore formation and therefore on autophagy 
initiation.  
The autophagy pathway starts with the formation of autophagosomes and could be 
divided in four steps:  initiation, nucleation, elongation and finally closure of the double-
membrane structure to form an autophagosome (Roberts and Ktistakis, 2013). The main 
kinase which regulate signals leading to autophagy initiation is mammalian target of 
rapamycin 1 (mTORC1) (Weidberg et al., 2011, Mizushima et al., 2011, Rubinsztein et al., 
2012, Kuballa et al., 2012). In fully fed condition mTORC1 is active and suppress 
autophagy by phosphorylating ULK1 on serine 757 (Roberts and Ktistakis, 2013). When 
nutrients are removed mTORC1 is inactive and these leads to ULK1 de – phosphorylation 
and to autophagy initiation (Roberts and Ktistakis, 2013). Together with ATG13 and 
FIP200, ULK1 constitute the ULK1 complex. The formation of this complex is essential for 
autophagy initiation and in starvation is recruited on the site of autophagosome 
formation (Mizushima et al., 2011). More recently, it has been demonstrated that also 
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the AMP activated protein kinase (AMPK) can phosphorylate ULK1, this phenomenon is 
even emphasized in the presence of mTORC1 inhibitor like rapamycin, meaning that 
mTORC1 negatively regulate this phosphorylation (Kim et al., 2011, Egan et al., 2011b). 
Furthermore, not only nutrient deprivation but also, intracellular Ca2+ levels can trigger 
autophagy by a Calmodulin- Dependent Kinase Kinase β (CaMKKβ)-mediated activation 
of AMPK without requiring a change in AMP or ADP levels (Hawley et al., 2005, Woods et 
al., 2005). It has been observed that different Ca2+ mobilizing agents, such as vitamin D, 
induce autophagy by CaMKKβ and AMPK phosphorylation and activation. Conversely, 
both pharmacological inhibition and genetic depletion of CaMKKβ causes the inactivation 
of AMPK and an attenuation of autophagy (Hoyer-Hansen et al., 2007). Thus, autophagy 
initiation is a balance among mTORC1 and AMPK, the first one suppresses ULK1 activity 
in nutrient-rich condition, whereas the phosphorylation by the second one can activate 
it (Egan et al., 2011a). After the recruitment of the ULK1 complex, the next complex 
required for autophagosome formation is the VPS34 complex 1 that is composed by 
phosphoinositide 3-kinase C (hVPS34 or PIK3C3), ATG14L, Beclin1 and phosphoinositide-
3-Kinase regulatory subunit 4 (hVPS15 or PIK3R4). PIK3C3 lipid kinase activity is crucial for 
phosphatidylinositol 3-phosphate (PtdIns(3)P) production (Mizushima and Komatsu, 
2011, Weidberg et al., 2011, Kuballa et al., 2012) since membranes enriched with 
PtdIns(3)P are thought to be the site of phagophore nucleation (Axe et al., 2008). 
Generation of PtdIns(3)P is a crucial step since it is necessary for the recruitment of 
several accessory proteins: double FYVE domain-containing protein 1 (DFCP1) (Ridley et 
al., 2001) and the WD-repeat protein interacting with phosphoinositides (WIPI) family 
(Proikas-Cezanne et al., 2004, Polson et al., 2010, Proikas-Cezanne et al., 2007). DFCP1 
possess an endoplasmic reticulum targeting domain and two FYVE domain required for 
PtdIns(3)P binding. When autophagy is induced DFCP1 translocates to the phagophore 
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nucleation site, and these structures partially colocalize with LC3 and ATG5 (Ridley et al., 
2001). DFCP1 recruitment on autophagosome generation site is inhibited by PI3K 
inhibitors such as wortmannin or 3-methyladenine, or by using siRNA targeting PIK3C3 
and Beclin1, indicating that both are required for PtdIns(3)P formation. On the other 
hand, the WIPI family members (WIPI1, WIPI2, WIPI3 and WIPI4) have been all implicated 
in autophagy (Proikas-Cezanne et al., 2004, Polson et al., 2010, Proikas-Cezanne et al., 
2007) with WIPI2 and WIPI4 (Proikas-Cezanne et al., 2004) behaving similarly to DFCP1 
(Roberts and Ktistakis, 2013). In addition, WIPI2 recruitment to the phagophore is 
necessary for the subsequent recruitment of lipidated LC3 during autophagosome 
maturation (Dooley et al., 2014).  Here we investigated the role of TRPML1 activation in 
the modulation of autophagy initiation. We found that TRPML1-mediated lysosomal 
calcium release promotes the recruitment of PtdIns(3)P-binding proteins to the 
autophagosome nucleation site during autophagy initiation in a process that requires 
calmodulin, CaMKKβ, and the subsequent activation of the ULK1 complex and the the 
PtdIns(3)-generating enzyme PIK3C3. We also found that the recruitment of PtdIns(3)-
binding proteins occurs in the close vicinity of TRPML1 activation in agreement the 
triggering of a local increase of lysosomal calcium in the phagophore nucleation site 
during autophagy initiation. 
Results and discussion 
TRPML1 regulates autophagosome biogenesis  
We have recently discovered a new lysosomal signalling pathway modulating autophagy 
that involves the release of lysosomal calcium through the activation of TRPML1 (Medina 
et al., 2015), a mechanism that may be important to sustain autophagy during starvation 
(Medina et al., 2015). Interestingly, we also preliminary observed that the acute silencing 
of TRPML1 significantly reduced the recruitment of PtdIns(3)P-binding reporter GFP-
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2xFYVE (Medina et al., 2015). PtdIns(3)P is a phosphoinositide detected at the surface of 
early endosomes, on intraluminal vesicles of multivesicular endosomes, and 
autophagosomes (Burman and Ktistakis, 2010, Di Paolo and De Camilli, 2006). Thus, 
during nutrient starvation the activation of the PIK3C3 complex, most likely in the ER 
increases the production and recruitment of PtdIns(3)P to the omegasome, the early 
precursor of autophagosomes (Knaevelsrud et al., 2013). Since PtdIns(3)P is an essential 
effector at the nascent autophagosome (Proikas-Cezanne et al., 2015), our observation 
may suggest that the activity of the lysosomal calcium channel TRPML1 plays a role in 
autophagosome biogenesis during autophagy initiation. First of all, we reproduced the 
data previously obtained by overexpressing the GFP-2xFYVE reporter (Medina et al., 
2015), by detecting endogenous WIPI2, a marker of autophagosome formation which is 
able to bind PtdIns(3)P too. We found that the acute silencing of TRPML1 by siRNAs 
reduces endogenous WIPI2 puncta formation upon starvation with EBSS (fig. 9 a). Then, 
as TRPML1 mutations cause the human lysosomal storage disease mucolipidosis IV 
(Bargal et al., 2000, Bassi et al., 2000), we investigated whether the recruitment of 
endogenous WIPI2 during starvation was also impaired in human MLIV fibroblasts from 
different patients (GM02525, GM02526). Indeed, we found a significant reduction in the 
induction of WIPI2 puncta formation during starvation compared with the normal 
starvation response in human WT cells. Similar reduction in the induction of WIPI2 puncta 
were obtained in a human cellular model of TRPML1 depletion, generated by 
CRISPR/Cas9, the haploid cell line hap1 (fig. 9 c), and after pharmacological inhibition of 




Figure 9: WIPI2 puncta are reduced in TRPML1 depleted cells. (a) Arpe19 cells silenced 72 hours or with a 
siRNA targeting a scramble sequence or one targeting TRPML1. Cells were then starved for 180 minutes 
with Ebss, in TRPML1 silenced cells WIPI2 puncta induction is reduced after starvation respect to scramble 
cells as also reported in the small bar plot on the right that represent the fold on the respective fed 
condition. (b) Immunofluorescence against endogenous WIPI2 on human fibroblasts wild type and MLIV 
(GM02526, GM02525). Cells were starved for 30 minutes and 180 minutes. In wild type cell, we observed 
a progressive increase in WIPI2 puncta formation by increasing the starvation time, MLIV cell lines, 
conversely, showed as the silenced one an impairment in the induction after both starvation time points. 
(c) Immunofluorescence against endogenous WIPI2 on hap1 cell line control and KO for TRPML1 with 
Crispr/Cas9 technology. Cells were starved for 30 minutes and 180 minutes. In control cell, we observed a 
progressive increase in WIPI2 puncta formation by increasing the starvation time, the KO cell line, 
conversely, showed an impairment in the induction after both starvation time points. (d) Arpe19 cells were 
treated overnight with 30µM of MLSI or DMSO. The day after cells were starved for 180 minutes with Ebss 
with DMSO or MLSI 30µM, in MLSI treated cells WIPI2 puncta induction is reduced after starvation respect 
to DMSO treated one, as also reported in the small bar plot on the right that represent the fold on the 
respective fed condition. 
 
To confirm that the impairment on the induction of WIPI2 was caused by a defect in 
autophagosome biogenesis we perform a similar experiment using the lysosomal 
inhibitor Bafilomycin A1 (BafA1) (fig. 10). We observed that the number of WIPI2 spots in 
TRPML1 silenced cells was not increased upon BafA1 treatment both in fed and in 
starvation, whereas, in scramble silenced cells we observed a further increase in WIPI2 




Figure 10: Arpe19 cells were silenced with a siRNA targeting TRPML1 or a scramble sequence (siSCR). After 
72 hours of silencing cells were starved or leave in complete medium whit or without the adding of BafA1 
for 4 hours. An immunofluorescence against endogenous WIPI2 was performed. The spots per cell were 
counted using ImageJ software. The plot on the right shows the mean value of WIPI2 spots/cell +/- sd. 
 
In addition, we further validated our results by performing, in collaboration with the 
TIGEM electron microscopy (EM) facility, an immunogold using an anti-WIPI2 antibody in 
both human WT fibroblast and MLIV patient cells (fig. 11 a, b). Indeed, we observed 
decreased number of WIPI2-positive structures after starvation in MLIV patient cells 
compared with their WT counterparts. Interestingly, while WT fibroblasts presented 
WIPI2-staining localized in electron dense pre-autophagosomal structure (Yla-Anttila et 
al., 2009) (fig. 11 a, arrows), in MLIV these structures were less abundant (fig. 11 b).  EM 
serial sections of the images showed aberrant structures in MLIV cells with a short finger-






Figure 11: Electron microscopy on human and MLIV (GM02526) fibroblasts. (a) Human fibroblasts wild type, 
four serial sections are shown. WIPI2 resides at the phagophore structure (arrows). (b) Human fibroblasts 
MLIV (GM02526), four serial sections are shown. WIPI2 associates with membranes of endoplasmic 




The reduction of WIPI2 puncta formation in MLIV cells were not due to a decrease of 
WIPI2 mRNA or protein levels, since quantitative PCR or western blots against WIPI2, in 
normal nutrient and starvation conditions resulted in similar WIPI2 protein levels in MLIV 
and WT fibroblasts (fig. 12 a, b).  
 
Figure 12:(a) Western blot against WIPI2 in total protein extract of human fibroblast control and MLIV 
(GM02526), no significant differences were observed in WIPI2 protein levels among the two cell lines and 
among the treatment as well. (b) Quantitative PCR on RNA from human fibroblast control and MLIV 
(GM02526). No significant differences were observed in WIPI2 mRNA levels among the two cell lines and 
among the treatment as well. As control we measured TRPML1 (MCOLN1) mRNA level and as expected was 
significantly downregulated. 
 
Together with WIPI2 protein we have also performed immunofluorescence for 
endogenous LC3 which is used to recognise the mature autophagosomes. It has been 
reported that in steady state nutrient conditions LC3-puncta is already accumulated in 
MLIV patient fibroblasts, most likely due to a downstream delay in the autophagic flux 
(Vergarajauregui et al., 2008a). We confirmed this observation in MLIV fibroblasts 
(GM02526) (fig. 13 a) when compared with WT cells (Ctr). Interestingly, we also observed 
that while in WT cells LC3-puncta progressively increased during starvation, in MLIV cells 
the number of LC3 spots slightly increase, confirming a block in the induction of 
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autophagy during starvation. In addition, we confirmed the delay in autophagosome 
degradation looking at the number of LC3 and LAMP1 positive puncta, which indicates 
autophagosomes fused with lysosomes (fig. 13 b). Also for autophago-lysosome there is 
no increase upon starvation in TRPML1 silenced cells.  
 
Figure 13: (a) Human fibroblasts wild type (Hf Ctr) and MLIV (GM02526) were starved for 30 and 180 
minutes or left untreated. After treatment, an immunofluorescence against endogenous LC3 was 
performed. The bar plot on the right show the fold induction on untreated condition of Hf Ctr. (b) Arpe19 
silenced 72 hours with a siRNA targeting TRPML1 or a scramble sequence, after silencing cells were feed 
or starved for 180 minutes. Cells were co-stained for endogenous LAMP1 and LC3. The bar plot shows the 




To further confirm the latter results we quantified the number of nascent 
autophagosomes by transfecting human ARPE-19 cells with a plasmid carrying the 
specific autophagic reporter DFCP1-GFP. In contrast to WIPI2 that can binds PtdIns(3)P, 
but may also interacts with PtdIns(3,5)P2 (Tsuruta, 2016), the DFCP1 protein contains 
two FYVE domains that bind specifically PtdIns(3)P, and colocalizes with the ER pool of 
this lipid identified as omegasome (Axe et al., 2008). We found that genetic depletion or 
pharmacological inhibition of TRPML1 channel significantly reduced the induction of 
DFCP1-positive vesicles upon starvation, compared to WT cells (fig. 14 a, b). Thus, these 
results suggest that the induction of autophagosome biogenesis during starvation is 
impaired in cells depleted for TRPML1 and in human MLIV cells, and this effect is most 
likely due to delayed recruitment of PtdIns(3)P-binding proteins to autophagosome 
nucleation sites (fig. 9). In order to discard that transient DFCP1-GFP overexpression may 
alter the recruitment/sequestering of endogenous PtdIns(3)P to membranes, we 
perfomed similar experiments using  stable HEK293 cells overexpressing DFCP1 GFP 
plasmid, this cell line was a gift of Dr. Ktistakis (Axe et al., 2008). In normal fed WT cells, 
we observed an increase in DFCP1 puncta formation upon starvation, whereas the 
silencing of TRPML1 significantly inhibits DFCP1-puncta during starvation, indicating that 
TRPML1 is involved in the recruitment of PtdIns(3)P-binding proteins DFCP1 and WIPI2 to 




Figure 14: DFCP1 recruitment is TRPML1 mediated. (a) Arpe19 cells silenced 72 hours or with a siRNA 
targeting a scramble sequence or one targeting TRPML1, the last 16 hours were transfected with DFCP1 
GFP plasmid. Cells were starved for 180 minutes and then number of DFCP1GFP structures were counted. 
A reduced number of vesicles were positive for DFCP1 GFP in cells depleted for TRPML1 (bar plot on right). 
(b) Arpe19 were treated overnight with 30µM of MLSI, at same time were transfected with DFCP1 GFP 
plasmid. Cells were starved for 180 minutes and then number of DFCP1GFP structures were counted. A 
reduced number of vesicles were positive for DFCP1 GFP in cells where TRPML1 activity was inhibited (bar 
plot on right). (c) Hek293 DFCP1 GFP cells were silenced 72 hours with a siRNA targeting a scramble 
sequence and one targeting TRPML1, then were starved 180 minutes. Number and size of DFCP1 GFP spots 
were counted and reported in the bar plots on right. (d) Quantitative PCR on Hek293 (left) and Arpe19 
(right) to show knock down efficiency of TRPML1 silencing. 
 
Then, we used a gain-function approach to investigate whether TRPML1 activation may 
activate the recruitment of WIPI2-positive autophagosomes in fed cells. First, we used 
pharmacological tools to activate TRPML1 by the treatment with the agonist MK6-83, 
kindly provided by Dr C. Grimm (Chen et al., 2014). We found that MK6-83 was able to 
promote endogenous WIPI2-puncta formation in two different cell lines in normal 
nutrient conditions (Hek293 and Arpe19) (fig. 15 a, b). Consistently, we also found that 
MK6-83 treatment induces LC3-puncta formation and elevation of autophagosomes 
colocalizing with lysosomes, indicating that direct activation of TRPML1 boost 
autophagosome-lysosomal fusion (fig. 15 c). Conversely, MLSI-mediated inhibition of 
TRPML1 inhibits autophagic flux and increases p62 accumulation (fig. 15 d). In addition, 
since MK6-83 can activates both TRPML1 and TRPML3 (Chen et al., 2014), we investigated 
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whether the WIPI2 puncta formation was selective towards TRPML1 by treating TRPML3 
KO Hap1 cells with MK6-83. We found that MK6-83 treatment induces similar WIPI2 
puncta in both WT and TRPML3 KO cells (fig. 15 e).  
Figure 15: (a) Arpe19 cells were treated with 30µM of MK6-83 for 180 minutes, then an 
immunofluorescence against endogenous WIPI2 was performed, as positive control I used cells starved for 
180 minutes. Number of spots were counted and normalized on cell number, in the bar plot on the right 
its reported the fold induction calculated on the DMSO. (b) Hek293 cells were treated with 30µM of MK6-
83 for 180 minutes, then an immunofluorescence against endogenous WIPI2 was performed, as positive 
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control I used cells starved for 180 minutes. Number of spots were counted and normalized on cell number, 
in the bar plot on the right its reported the fold induction calculated on the DMSO. (c) Arpe19 cells were 
treated with 30µM of MK6-83 for 180 minutes, then an immunofluorescence against endogenous LAMP1 
and LC3 were performed. DMSO and TORIN1 were used as negative and positive control respectively. 
Number of spots were counted and normalized on cell number, in the bar plot on the right its reported the 
fold induction calculated on the DMSO. (d) Western blot of insoluble fraction of human fibroblast control 
untreated or treated overnight with MLSI, 180 minutes of starvation and GM02048 (MLIV cell line) were 
used as positive and negative control for cellular clearance respectively. the western show the 
accumulation of two autophagic cargo NBR1 and P62. The bar plot shows the fold calculated on the 
untreated. (e) Hap1 control and TRPML3 KO were treated with MK6-83 for 3 hours. After fixation, an 
immunofluorescence against endogenous WIPI2 were performed. The plot on the right showed the 
percentage of cells that showed more than 2 WIPI2 puncta per cell. The experiment was performed twice.   
 
Then, we overexpressed a vector carrying WT TRPML1 fused to the GFP (TRPML1-GFP) in 
human ARPE19 cells (fig. 16 a). Similarly to agonist-mediated TRPML1 activation, the 
overexpression of TRPML1-GFP promoted the formation of WIPI2-puncta while the 
overexpression of a TRPML1 non-conducting pore mutant (D471K/D472K; abbreviated 
TRPML1-DDKK) (Cao et al., 2017) was not able to increase the recruitment of WIPI2 to 
vesicle structures (fig. 8 b). Interestingly, most of the WIPI2-positive vesicles were closely 
to lysosomal localized TRPML1-GFP lysosomes, suggesting that PtdIns(3)P nucleation 
occurs in the vicinity of TRPML1 activation (fig. 16 b, c). Interestingly, a recent work from 
Biazik et al showed that in addition to ER, recycling endosomes and golgi, WIPI2-
phagophores frequently form in close vicinity to late endosomes or lysosomes (Biazik et 
al., 2015). Thus, we used super resolution microscopy analysis to further confirm the 
closed vicinity of endogenous WIPI2-puncta to the lysosomes expressing TRPML1-GFP 
(fig. 16 c). Interestingly, TRPML1-mediated induction of WIPI2-puncta was also localized 
in the close proximity of the endoplasmic reticulum (ER), the major organelle involved in 
phagophore membrane source. Based on these results we reasoned that upon TRPML1 
activation a local increase of lysosomal calcium may induce PtdIns(3)P recruitment in the 
proximity of the ER. Thus, we decided to silence the endoplasmic reticulum-localized 
Vesicle associated membrane proteins (VAMP)-Associated Proteins (VAPs) that have 
been implicated in tethering numerous different membrane contact sites (Eden, 2016). 
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We observed that upon VAPs (VAP-A/B) silencing we reduce the TRPML1-mediated WIPI2 
puncta formation via MK6-83 treatment (fig. 16 d). These results suggest that TRPML1 
activation induces phagophore formation in the very close vicinity of the ER most likely 
forming contact sites with this organelle.  
 
Figure 16: Genetic or pharmacological activation of TRPML1 promotes WIPI2 spots. (a) Arpe19 cells 
transfected with TRPML1 GFP and stained with endogenous LAMP1. White box and white arrow show the 
correct localization of TRPML1 on lysosomes. (b) Arpe19 cells were transfected 24 hours with TRPML1 GFP 
or TRPML1 DDKK GFP, then an immunofluorescence against endogenous WIPI2 were performed, on the 
right the first bar plot on the top show the number of WIPI2 spots in transfected cells, the second plot on 
the bottom show the Manders overlap coefficient (MOC) between WIPI2 and the GFP. (c) Arpe19 
transfected with TRPML1 GFP were fixed and stained for endogenous endoplasmic reticulum marker PDI 
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(red) and WIPI2 (blue). Images were acquired with LSM880 super resolution using SIM, after acquisition a 
3D reconstruction has been performed. (d) HeLa cells were treated 72 hours with an siRNA targeting VAP-
A/B or with an siRNA scramble. Cells were left untreated or treated with MK6-83. An immunofluorescence 
against endogenous WIPI2 was performed. The bar plot on the right shows the number of spot per cell +/- 
standard deviation. (e) western blot of HeLa treated 72 hours with an siRNA targeting VAP-A/B or with an 
siRNA scramble, to show knock down efficiency.  
  
TRPML1-mediated Autophagosome biogenesis requires a calcium-dependent 
pathway involving Calmodulin and CAMKKβ  
Since TRPML1 is a lysosomal Ca2+ channel, and we already observed that a TRPML1 pore 
mutant was unable to induce WIPI2 puncta formation (figure 16 b), we investigated 
whether calcium chelation may impair WIPI2-puncta induction upon TRPML1 activation. 
We first, confirmed the requirement of Ca2+ during starvation-mediated autophagy 
induction (fig. 9). Hen, by using a fast calcium chelator, BAPTA-AM, we were able to 
completely block WIPI2 puncta formation upon starvation (fig. 17), while the use of a 
slower kinetic chelator, EGTA, was ineffectively inhibiting such formation (fig. 17). Then, 
we link these observations with TRPML1 activity, and therefore the co-treatment of MK6-
83 agonist with BAPTA-AM completely block TRPML1-dependent recruitment of WIPI2 to 
autophagosomes. Altogether, we confirm the role of lysosomal calcium release, through 




Figure 17: WIPI2 puncta formation is Ca2+- and PI3K- Dependent. Human fibroblasts wild type was starved 
for 30 and 180 minutes with or without BAPTA or EGTA. An immunofluorescence against endogenous WIPI2 
was performed. Number of spots were counted and normalized on cell number, in the bar plot on the right 
it is reported the fold induction calculated on the DMSO, the experiment was performed 3 times.  
 
Ca2+/calmodulin-dependent protein kinase kinase β(CaMKKβ) has been involved in the 
autophagic pathway (Hawley et al., 2005, Woods et al., 2005), thus we decide to use both 
STO-609, a selective inhibitor of CaMKKβ (Tokumitsu et al., 2002), and Calmidazolium 
(CMDZ) an inhibitor of calmodulin (CaM), which inhibits CaM-dependent 
phosphodiesterase (Gietzen, 1983). Starvation-mediated WIPI2 puncta formation was 
significantly reduced when cells are co-treated with STO-609 and CMDZ, respectively (fig. 
18 a). Similarly, LC3 puncta formation was significantly reduced in the presence of STO-
609 and CMDZ, suggesting that these calcium-dependent proteins are involved in the 
induction of autophagy upon nutrient deprivation conditions. We discard any effect of 
these drugs on mTOR pathway by measuring the phosphorylation of pS6 ribosomal 




Figure 18: (a) Arpe19 cells were starved with or without STO-609 and CMDZ. An immunofluorescence 
against endogenous WIPI2 and LC3 was performed. In the lower panel of the figure bar plots shows the 
fold on Fed condition. (b) Arpe19 were treated with STO6-09 and BAPTA-AM in complete medium or 
starved in co-treatment with STO6-09, BAPTA-AM. Dmso was used as control of mTORC1 activity, Torin1 
and Hbss were used as control for mTORC1 inactivation. An immunofluorescence against pS6 ribosomal 
protein was performed, the mean intensity was measured and reported in the bar plot on the right. 
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Since it has been proposed that CaMKKβ induces autophagy throught the 
phosphorylation of AMPK on threonine 172 (Woods et al., 2005), we asked whether 
TRPML1 calcium release could be involved in Ca2+- mediated AMPK activation via 
phosphorylation of T172. Indeed, we found that pharmacological activation of TRPML1 
channel activity with MK6-83 induced phosphorylation of AMPK on threonine 172 (T172) 
in a dose-response manner (fig. 19 a). Furthermore, using the concentration of MK6-83 
which induces the highest AMPK phosphorylation, we found that while AMPK is 
phosphorylated, mTORC1 substrates were not altered (figure 19 a, b). In addition, the 
acute silencing of TRPML1 inhibits AMPK phosphorylation upon MK6-83 activation, 
confirming the selectivity of TRPML1-mediated activation of AMPK phosphorylation (fig. 
19 a). Together, we propose that TRPML1-mediated induction of autophagosome 
formation requires Calmodulin and CaMKKβ activation, and the subsequent 
phosphorylation of AMPK. 
 
Figure 19: Pharmacological activation of TRPML1 induce AMPK phosphorylation. (a) Western blot showing 
Arpe19 total protein extract treated with increasing concentration of MK6-83 (from 0 to 60µM). To test 
the specificity of MK6-83 a sample silenced 72 hours for TRPML1 was used as negative control. Dose 
response effect of MK6-83 on AMPK phosphorylation was showed in the bar plot on the right. (b) Western 
blot showing Arpe19 total protein extract treated with 30µM of MK6-83, Torin1 treatment was used as 
control for mTORC1 inactivation. 
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PIK3C3 complex is assembling but is less active 
The recruitment of WIPI2 and DFCP1 to the nascent autophagosome requires the 
generation of PtdIns(3)P by the autophagic protein complex PIK3C3 (Marat and Haucke, 
2016). Moreover, the recruitment of WIPI2 and DFCP1 is sensitive to PI3K inhibitors, such 
as wortmannin (Powis et al., 1994). Indeed, we found that wortmannin was able to block 
WIPI2 puncta formation in cells treated with the TRPML1 activator MK6-83 (fig. 20), 
suggesting that the induction of autophagosome formation during TRPML1 activation is 
PIK3-dependent. 
Figure 20: WIPI2 puncta formation is Ca2+- and PI3K- Dependent. Arpe19 cells were treated with 30µM of 
MK6-83 for 180 minutes in co-treatment with BAPTA or wortmannin. An immunofluorescence against 
endogenous WIPI2 was performed. Number of spots were counted and normalized on cell number, in the 
bar plot on the right its reported the fold induction calculated on the DMSO. 
 
Then, we investigated whether the formation of the autophagic PIK3C3 protein complex 
might be altered in the absence of TRPML1. Thus, we decided to perform a proteomic 
approach by immunoprecipitating the catalytic subunit VPS34 in both Hap1 WT and Hap1 
depleted of TRPML1 cells. Proteomic results clearly showed that there were not 
significant differences in the formation of PIK3C3 complex in TRPML1 KO cells, since all 
the major members (Beclin1, and PIK3R4) were present together with UV irradiation 
resistance-associated gene (UVRAG), which has been proposed to positively regulates 
autophagic flux (Liang et al., 2006) (Fig. 21 a; tab.  2 and 3). Indeed, we validated these 
results by immunoprecipitation of the PIK3C3 complex in both cell lines (fig. 21 b, c). Then, 
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we asked whether TRPML1 inhibition may reduce the activity of the PIK3C3 by monitoring 
its activity. The experiment was performed in both acute silenced of Arpe19 cells using 
TRPML1 siRNAs, and in WT or TRPML1 KO Hap1 cells. Upon PIK3C3 immunoprecipitation 
we determine the amount of PtdIns(3)P produced. In TRPML1 silenced cells the amount 
of PtdIns(3)P produced was lower if compared with the scramble silenced cells (fig. 21 d). 
Similarly, in Hap1 TRPML1 KO cells the PtdIns(3)P levels were not detectable compared 
with WT cells (fig. 21 e). Detection of similar PIK3C3 protein levels by immunoblotting of 
the same immunoprecipitates confirm the presence of PIK3C3 in the different samples 
(fig. 21 d, e). Thus, we conclude that TRPML1 may modulate WIPI2 and DFCP1 
recruitment to the nascent autophagosome by regulating the activity of the autophagic 
protein complex PIK3C3. 
 
Figure 21: Proteomic analysis on PIK3C3 and PIK3C3 kinase assay. (a) volcano plots show enriched protein 
compared with control mouse IgG, red spots represent non-specific binding (protein equally present in the 
mouse IgG), blue spots represent the specific protein enriched. In the plot, the immunoprecipitated protein 
is written in red, the other member of PIK3C3 complex are written in black, a complete list of all hits is 
reported in table 1 and 2. (b) western blot showing immunoprecipitation of PIK3C3 in Hap1 Ctr and TRPML1 
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KO, the immunoprecipitation was performed in fed and during starvation (c) western blot showing 
immunoprecipitation of PIK3C3 in Hap1 Ctr and TRPML1 KO, the immunoprecipitation was performed only 
in starvation, in this blot there is also a lane for the mouse IgG for both cell lines.  
 
TRPML1 is required for the localization of ULK1 complex on the isolation 
membrane 
PIK3C3 and its enzymatic product PtdIns(3)P is required, directly or indirectly, for the 
recruitment of multiple autophagy components (WIPI1, ZFYVE1/DFCP1, ATG5 and LC3) 
to forming autophagosomes (Polson et al., 2010, Matsunaga et al., 2010). It has been 
demonstrated that the recruitment of PIK3C3 is mediated by the ULK1 complex. Together 
the complexes are necessary for the correct autophagy initiation. The ULK1 complex is 
composed by ULK1, ATG13 and FIP200 and plays a central role in starvation-induced 
autophagy, it integrates signals from upstream sensors such as mTOR and AMPK and 
transduces them to the downstream autophagy pathway (Wong et al., 2013). ATG13 is 
required for the correct localization of the ULK1 complex on the phagophore membrane 
(Karanasios et al., 2016), thus we used stably ATG13 HEK293 to follow the ULK1 complex 
during starvation in both normal or TRPML1 depleted cells. In WT cells in normal nutrient 
conditions ATG13 GFP was mainly distributed all around the cytoplasm, whereas during 
starvation ATG13 was recruited to a vesicular compartment (Fig. 22). Conversely and in 
agreement with its role in autophagy initiation, TRPML1 depletion significantly reduced 
ATG13-GFP puncta formation during starvation (fig. 22), suggesting that TRPML1 




Figure 22: Hek293 ATG13 GFP cells were silenced 72 hours with a siRNA targeting a scramble sequence and 
one targeting TRPML1, then were starved 180 minutes. Number of ATG13 GFP spots were counted and 
normalized on cell number as showed in the bar plots on right. An additional bar plot is added and its 
showing silencing efficiency of TRPML1 by quantitative PCR.  
  
Conclusion 
Although both calcium signaling and the lysosomal calcium channel TRPML1 have been 
already involved in autophagy, these data have been controversial and fragmented in 
many aspects. In this work we have described how TRPML1 calcium release is crucial for 
TFEB activation via calcineurin, promoting the transcription of autophagic and lysosomal 
genes (Medina et al., 2015). This pathway may be crucial for the sustaining of autophagy 
during autophagy. In addition, here we have described a novel role for TRPML1 mediated 
lysosomal calcium release in the modulation of autophagy initiation during starvation. 
Thus, by using both loss-of-function and gain-of-function approaches we showed that 
TRPML1 is required for the recruitment of PtdIns(3)P-binding proteins DFCP1 and WIPI2 
on the nascent autophagosome membrane. In addition and in agreement with a local 
increase on lysosomal calcium release upon TRPML1 activation, nascent 
autophagosomes forms in the close proximity of lysosomes and ER regions, suggesting 
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that PtdIns(3)P nucleation occurs in the vicinity of TRPML1 activation. Hence, silencing of 
VAPs, implicated in tethering of numerous different membrane contact sites with ER, 
consistently reduce TRPML1-mediated WIPI2 puncta formation upon MK6-83-mediated 
activation of TRPML1. Looking at the potential pathways activated during TRPML1-
mediated induction of autophagosome formation we found that this process requires 
both calmodulin and CaMKKβ. We propose that CaMKKβ induces AMPK phosphorylation 
and therefore the phosphorylation of downstream ULK1 complex, an essential complex 
during autophagy initiation. Indeed, by looking at the ULK1 protein partner ATG13, we 
found that the silencing of TRPML1 inhibits ATG13-recruitment to vesicles during 
starvation. WIPI2 puncta formation requires the generation of PtdIns(3)P by PIK3C3, and 
we found that although the assembly of this complex is not altered in cells depleted of 
TRPML1, its activity was significantly reduced compared with WT cells. Therefore, we 
propose a working model where we hypothesize that during starvation TRPML1 releases 
lysosomal calcium that activates a calcium-dependent pathway involving CaMKKβ/AMPK 
signalling that promotes the induction of two essential protein complexes involved in 
autophagy initiation such as ULK1 and PIK3C3 complexes (fig. 23). In addition, this 
signaling may be important in the pathology of MLIV disease, is impaired in MLIV 
fibroblast, and open novel therapeutic opportunities to rescue autophagy induction by 
using small molecules or calcium ionophores that may bypass TRPML1 disfunction. 
Therefore, calcium elevating agents such as curcumin has been used in LSDs like NPC 
disease to rescue lipid accumulation (Lloyd-Evans et al., 2008). Interestingly, TRPML1 
activity is inhibited in NPC cells due to the accumulation of sphingosine within lysosomes. 
Thus, further characterization of autophagy initiation in NPC may reveal similar 
impairment in the formation of phagophores that can be rescued by promoting 




Figure 23: Supposed working model. Calcium release via TRPML1 (mediated by Hbss or MK6-83) act on 
several processes. (1) Lysosomal calcium via TRPML1 activate PPP3CB which dephosphorylate TFEB that 
translocate into the nucleus activating the transcription of lysosomal/autophagic genes and in turn 
modulate TRPML1 too (Medina et al., 2015). (2) Calcium release via TRPML1 could activate CaMKKβ which 
could act on AMPK that phosphorylate ULK1 that activate autophagic flux via PIK3C3 complex which 
produce PtdIns(3)P that in turn recruit its effector WIPI2 and DFCP1 required for autophagy initiation. 
 
Methods  
Drugs and cellular treatments 
The following drugs were used to perform the assays: Torin1 (1uM, otherwise indicated) 
from Tocris Bioscience; BAPTA – AM (10uM) from Invitrogen; EGTA – AM (5uM) from 
Santa Cruz biotechnology; MK6-83 (30uM) a gift of Dr. C. Grimm; Bafilomycin A1 (400n) 
from SIGMA; STO-609 (20uM) from Cayman Chemical; CMDZ (10uM) from Cayman 
Chemical; wortmannin (5uM) from SIGMA; the starvation medium was prepared with 
HBSS (Invitrogen), 10mM HEPES (SIGMA). 
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Cell culture, plasmids and siRNA transfection  
Arpe 19, Hek 293 were purchased at ATCC and cultured in DMEM F12 or DMEM 
supplemented with 10% fetal bovine serum, 200uM L – glutamine, 100uM sodium 
pyruvate, 5% CO2 at 37°C. HAP1 (TRPML1 KO; TRPML3 KO; Ctr) were purchased at 
Horizon and cultured in IMDM supplemented with 10% fetal bovine serum, 200uM L – 
glutamine, 100uM, , 5% CO2 at 37°C. Human patient fibroblast CTR, GM02526, GM02525 
were purchased at Coriell institute and cultured in DMEM supplemented with 15% fetal 
bovine serum, 200uM L – glutamine, 5% CO2 at 37°C. Hek293 DFCP GFP and Hek 293 
ATG13 GFP were a gift of Dr Ktistakis and were cultured in DMEM supplemented with 
10% fetal bovine serum, 200uM L – glutamine, 100uM sodium pyruvate, 0.8 mg/mL of 
G418 , 5% CO2 at 37°C. Cells were silenced with 50nM of siRNA against TRPML1 
(sequence: CCUUCGCCGUCGUCUCAAA); VAP-A (sequences: CCACAGACCUCAAAUUCAA; 
GGCAAAACCUGAUGAAUUA; CCUGAGAGAUGAAGGUUUA; CAAGGAAACUAAUGGAAGA) 
and VAP-B (sequences: GUAAGAGGCUGCAAGGUGA; CCACGUAGGUACUGUGUGA; 
UGUUACAGCCUUUCGAUUA; GUAAUUAUUGGGAAGAUUG) for 72 hours using 
Lipofectamine RNAimax from Invitrogen according to the protocol from manufacture. 
The plasmid DFCP1 – GFP was a gift of Dr. Carmine Settembre (TIGEM), the plasmid 
TRPML1 DDKK GFP was a gift of Dr. Xu (Cao et al., 2017). TRPML1 GFP was generated sub 
cloning the TRPML1 CDS (OriGene) in the PE GFP C3 from Invitrogen between XhoI and 
EcoRI.  
Antibodies and western blotting  
For western blots, the following antibodies were used: B-Actin (AC-15, cat. A5441, 
1:4000), NBR1 (cell signalling cat. 9891, 1:1000), p62 (BD cat. 610833, 1:1000), WIPI2 
(Abcam cat. ab105459, 1:1000), LC3 (Novus NB100-2220, 1:1000), ULK1 (cell signalling 
cat. 8054 1:1000), Phospho-ULK1 (Ser757) (cell signalling cat. 6888 1:1000), Phospho-
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ULK1 (Ser555) (cell signalling cat. 5869 1:1000), p70 S6 Kinase (cell signalling cat. 2708 
1:1000), Phospho-p70 S6 Kinase (Thr389) (cell signalling cat. 9205 1:1000), S6 Ribosomal 
Protein (cell signalling cat. 2317 1:1000), Phospho-S6 Ribosomal Protein (Ser240/244) 
(cell signalling cat. 5364 1:1000), Phospho-AMPKα (Thr172) (cell signalling cat. 2535 
1:1000), AMPKα (cell signalling cat. 5831 1:1000), VAP-A and VAP-B was provided by Dr. 
Antonella De Matteis laboratory (TIGEM).  
Total cell lysate was prepared by solubilization in TRIS HCl 10mM pH 8.0 and 0.2% SDS 
supplemented with protein and phosphatases inhibitor (SIGMA). To generate soluble and 
insoluble fraction the protocol used was described in Vergarajauregui S. et al. 2008 
(Vergarajauregui et al., 2008a). Protein concentration was determined by the Bradford 
method. 
After SDS-PAGE and immunoblotting the protein recognised by the specific antibody 
were visualized by chemiluminescence methods (Luminata Crescendo Western HRP 
substrate, Millipore) using peroxidase-conjugated anti-rabbit or anti-mouse secondary 
antibodies (Calbiochem). Membranes were developed using a Chemidoc UVP imaging 
system (Ultra-Violet Products Ltd) and densitometric quantification was performed in 
unsaturated images using ImageJ (NIH).  
Immunofluorescence  
For immunofluorescence, the following antibodies were used: WIPI2 (Abcam cat. 
ab105459, 1:1000), LC3 (cell signalling cat. 2775, 1:100), LAMP1 (Santa Cruz cat. sc-
20011, 1:400), PDI (cell signalling cat. 3501s, 1:200), pS6 ribosomal protein (cell signalling 
9865s 1:400) 
Cells were fixed with ice cold methanol for 5 minutes on ice and permeabilized in 0.1% 
(w/v) saponin, 0.5% (w/v) BSA and 50 mM NH4Cl in PBS (blocking buffer). Cells were 
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incubated with the indicated primary antibodies for 1 hour and subsequently incubated 
with secondary antibodies. For confocal imaging, the samples were examined under a 
Zeiss LSM 800 confocal microscope. Optical sections were obtained under a ×63 
immersion objective at a definition of 1024 × 1024 pixels (average of eight or sixteen 
scans), adjusting the pinhole diameter to 1 Airy unit for each emission channel to have all 
the intensity values between 1 and 254 (linear range). For image analysis Columbus 
software (Columbus 2.6.0.127073 © Copyright 2008-2017 PerkinElmer) was used.   
For super resolution images, samples were examined under a Zeiss LSM 880 super 
resolution microscope. Optical sections were obtained under a ×63 immersion objective 
1.4 oil DIC. To perform 3D reconstruction, we acquired images with pixel size of 0.064µm 
(x and y), z-step size 0.21 µm (12 images for z-stack). All post processing and 3D 
reconstruction of the image were performed using ZEN software (Zeiss).  
Immuno-electron microscopy 
Cells were fixed in a mixture of 4% paraformaldehyde and 0.05% glutaraldehyde prepared 
in 0.2 M Hepes. Then the cells were washed and incubated with the blocking/ 
permeabilizing mixture (0.5% BSA, 0.1% saponin, 50 mM NH4Cl) for 30 min and 
subsequently with the primary antibody against WIPI2, diluted 1:100 in blocking/ 
permeabilizing solution, overnight. The following day the cells were washed and 
incubated with the secondary antibody, the anti-rabbit Fab’ fragment coupled to 1.4-nm 
gold particles, diluted 1:50 in blocking/ permeabilizing solution, for 2 h. After this 
incubation with the antibodies, the gold-enhancement reaction has to be performed to 
increase the size of the 1.4-nm gold particles. Then samples were post-fixed in a mixture 
of osmium tetroxide and potassium ferrocyanide, dehydrated in ethanol and acetone and 
embedded in epoxy resin as described previously (Polishchuk et al., 2014). Thin 60 nm 
serial sections were cut using a Leica EM UC7 ultramicrotome. EM images were acquired 
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using a FEI Tecnai-12 electron microscope (FEI, Eindhoven, Netherlands) equipped with 
a VELETTA CCD digital camera (Soft Imaging Systems GmbH, Munster, Germany). 
RNA extraction and quantitative PCR.  
Total RNA was extracted from cells using RNeasy Plus Mini Kit (Qiagen). Reverse 
transcription was performed using QuantiTect Rev Transcription Kit (Qiagen). Real-time 
quantitative Reverse Transcription PCR (qRT-PCR) was performed using the LightCycler® 
System 2.0 (Roche Applied Science). HPRT was used for qRT-PCR as reference gene. The 
parameters of real-time qRT-PCR amplification were according to Roche 
recommendations. The following primers were used in this study: HPRT fw: 
tggcgtcgtgattagtgatg, rev: aacaccctttccaaatcctca; TRPML1 fw: gagtgggtgcgacaagtttc, rev: 
tgttctcttcccggaatgtc; WIPI2 fw: tacctgccttcccaagtgac, rev: agcgagcagatgtttttgtg. 
DFCP1 GFP Assay 
 Arpe19 cells were transfected with TRPML1 or scramble control siRNA using RNAiMax. 
48h later the cells transfected with the DFCP1 - GFP construct using Lipofectamine LTX 
and Plus (Invitrogen), and 24h later serum starved and fixed with ice cold methanol for 5 
minutes. Imaging was performed with a 63x Plan Apochromat NA 1.4 DIC oil immersion 
objective on an LSM 800 confocal microscope (Zeiss). For image analysis Columbus 
software (Columbus 2.6.0.127073 © Copyright 2008-2017 PerkinElmer) was used. 
PIK3C3 Immunoprecipitation, proteomic and kinase activity  
After plating cells were starved for 1 hour to increase PIK3C3 complexes. After starvation 
cells were washed one in ice cold PBS and then twice with Buffer A (20mM TRIS-HCl pH 
7.5; 137mM NaCl; 1mM MgCl2; 1mM CaCl2; 100mM NaF; 10mM Na pyrophosphate; 
100uM Na3VO4). Cells were lysed 20 minutes in Buffer A supplemented with 1% NP-40; 
10% Glycerol and protease and phosphatase inhibitor (buffer recipe from Echelon). After 
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10 minutes of centrifugation at max speed 4°C, supernatant was collected and quantified 
as described in antibodies and wester blotting. 2mg of protein extract was incubated o/n 
at 4°C with 2ug of PIK3C3 antibody (Santa Cruz cat. SC365404). Subsequently 40uL of 
protein A/G agarose conjugated (Santa Cruz cat. SC2003) was incubated for 2h at 4°C. 
Once the immunoprecipitation was completed the PIK3C3 enzyme bound to the agarose 
beads was used for western blot analysis, proteomic and PIK3C3 kinase assay. For 
western blot and proteomic, the enzyme was eluted by adding sample buffer 2X and 
boiled 5 minutes at 95°C, then was separated on acrylamide gel. For proteomic analysis, 
we send the gel to EMBL facility in Hidelberg. For PIK3C3 kinase activity we use Cell III PI3-




 Table 2: Complete proteomic hits list. This table shows the protein enriched in the Ip of PIK3C3 in Hap1 Ctr 
cells and was obtained normalizing the results with an Ip of Mouse IgG in the same cell lines. A linear 
modeling approach was used to analyze the data using the limma package in R/Bioconductor. 
 
 
Table 3: Complete proteomic hits list. This table shows the protein enriched in the Ip of PIK3C3 in Hap1 
TRPML1 KO cells and was obtained normalizing the results with an Ip of Mouse IgG in the same cell lines. A 
linear modeling approach was used to analyze the data using the limma package in R/Bioconductor. 
 
Gene name Description  logFC P.Value 
DLST Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
1.23E+00 2.07E-06 
EIF2AK2 Interferon-induced, double-stranded RNA-activated protein kinase 8.21E-01 3.30E-06 
UVRAG UV radiation resistance-associated gene protein 8.07E-01 4.46E-06 
OGDH 2-oxoglutarate dehydrogenase, mitochondrial 7.91E-01 6.90E-06 
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 1.08E+00 7.15E-06 
PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 1.05E+00 7.91E-06 
CBFA2T2 Protein CBFA2T2 9.27E-01 1.12E-05 
BECN1 Beclin-1 1.04E+00 1.60E-05 
EML3 Echinoderm microtubule associated protein like 3, isoform CRA_e 6.93E-01 2.27E-05 
GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 8.05E-01 2.75E-05 
Gene name Description  logFC P.Value 
EIF2AK2 Interferon-induced, double-stranded RNA-activated protein kinase 1.02E+00 9.60E-07 
UVRAG UV radiation resistance-associated gene protein 8.80E-01 2.73E-06 
TAF15 TATA-binding protein-associated factor 2N 7.53E-01 5.20E-06 
DLST Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
1.04E+00 5.47E-06 
DKC1 H/ACA ribonucleoprotein complex subunit 4 6.42E-01 6.65E-06 
OGDH 2-oxoglutarate dehydrogenase, mitochondrial 7.82E-01 7.36E-06 
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 1.07E+00 7.70E-06 
EML3 Echinoderm microtubule associated protein like 3, isoform CRA_e 8.38E-01 7.87E-06 
GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 9.88E-01 8.74E-06 
BECN1 Beclin-1 1.14E+00 9.32E-06 
PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 1.01E+00 9.65E-06 
NOP58 Nucleolar protein 58 6.25E-01 1.16E-05 
CAPRIN1 Caprin-1 6.19E-01 2.42E-05 
NOP56 Nucleolar protein 56 8.00E-01 2.89E-05 
CBFA2T2 Protein CBFA2T2 7.31E-01 4.23E-05 
MATR3 Matrin-3 6.25E-01 2.00E-04 
RASAL2 Ras GTPase-activating protein nGAP (Fragment) 8.96E-01 2.03E-04 
LMNB1 Lamin-B1 6.67E-01 3.62E-04 
HIST1H3A Histone H3.1 1.35E+00 1.62E-03 
RTCB tRNA-splicing ligase RtcB homolog 7.36E-01 2.02E-03 
HIST1H4A Histone H4 1.34E+00 3.57E-03 






TRPML1 as target for treating lysosomal storage diseases: a high 
content screening approach 
Abstract  
In this work, we have investigated the role of TRPML1-mediated lysosomal signaling in 
the modulation of the autophagic and lysosomal pathways. We have found that TRPML1 
modulates autophagy at the transcriptional level by inducing TFEB at the initial steps of 
autophagosome formation during starvation. Since mutations in TRPML1 cause a severe 
human LSD, called mucolipidosis type IV (Sun et al., 2000, Bassi et al., 2000, Bargal et al., 
2000), our findings might be of interest to develop novel therapeutic approaches to 
identify correctors of cellular defects related with this disease.  Thus, we investigated two 
different approaches; 1) Identify TFEB inducers in MLIV cells from a collection of FDA 
drugs able to promote TFEB nuclear translocation in WT cells, and; 2) Develop a primary 
high content screening assay aimed at identifying FDA-compounds promoting the 
clearance of cholesterol in human MLIV cells. Together, these two screening assays 
resulted in the identification of 9 compound hits able to restore TFEB signalling and 
promote lipid storage clearance in human fibroblast from MLIV patients. 
Introduction 
Lysosomes are membrane-bound organelles that contain an acidic lumen and several 
hydrolases that are devoted to the degradation of specific substrates. In addition, the 
lysosomal membrane contains proteins that are involved in the transport of substances 
into and out of the lumen, acidification of the lysosomal lumen and fusion of the lysosome 
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with other cellular structures. In addition to the central role of lysosomes in the 
degradation of extracellular and intracellular substrates, lysosomes can also secrete their 
content by fusing with the plasma membrane (lysosomal exocytosis), and recently the 
lysosome has been implicated in nutrient sensing and in signalling pathways that are 
involved in cell metabolism and growth (Settembre et al., 2012, Settembre et al., 2013). 
Lysosomal dysfunction has been associated with several human diseases, as well as with 
the process of ageing, which may be associated with a decline in lysosomal function and 
a progressive accumulation of intracellular material (for example, lipofuscin and 
ubiquitin). Thus, genetic defects in specific lysosomal components lead to the 
accumulation of substrates that are not degraded in the lysosomal lumen, followed by 
progressive lysosomal dysfunction in several tissues and organs. These disorders are 
known as lysosomal storage diseases (LSDs). Approximately 60 different types of LSDs 
have been recognized. Historically, LSDs have been classified on the basis of the type of 
material that accumulates in the lysosomes, such as mucopolysaccharides, sphingolipids, 
glycoproteins, glycogen and lipofuscins. LSDs often show a multisystemic phenotype that 
is associated with severe neurodegeneration, mental decline, cognitive problems and 
behavioural abnormalities. More than 20 loss-of-function (LOF) mutations of TRPML1 
have been associated with a LSD called mucolipidosis type IV (MLIV) which is 
characterized by psychomotor retardation and achlorhydria (Xu and Ren, 2015, Altarescu 
et al., 2002). The symptoms typically manifest in the first years of life, and there is still no 
cure to treat patients affected by this disorder. MLIV-affected cells show accumulation of 
aberrant lysosomes filled with auto-fluorescent lipid material, including cholesterol (Li et 
al., 2016).  In addition, lysosomal dysfunction results in a partial block of autophagy that 
is characterized by the accumulation of autophagic markers such as LC3 and p62 
(Vergarajauregui et al., 2008a). Interestingly, both the accumulation of lipids as well as 
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disturbed lysosomal Ca2+ homeostasis have been described in different LSDs and in some 
cases, have been proposed to involve TRPML1.  Indeed, it has been demonstrated that in 
Niemann-Pick type A-C disease, the prolonged accumulation of cholesterol, 
sphingomyelins, sphingosine and glycosphingolipids leads to the progressive impairment 
of TRPML1 function suggesting that defective TRPML1 activity may be part of the 
pathogenic mechanisms in many LSDs (Xu and Ren, 2015) (Shen et al., 2012).  
 In chapter 1 of my thesis we have demonstrated the existence of a signalling that starts 
at the lysosomes in which Ca2+ release via TRPML1 plays a major role in lysosomal 
adaptation to starvation by activating the Ca2+-dependent phosphatase calcineurin that 
de-phosphorylates TFEB inducing its nuclear translocation (Medina et al., 2015). Most 
importantly, it has been showed that TFEB overexpression promotes cellular clearance in 
different LSDs by inducing lysosomal exocytosis, a process that also requires TRPML1-
dependent Ca2+ release (Medina et al., 2011). Indeed, TFEB overexpression increases the 
number of the lysosomes in the proximity of the plasma membrane and promotes their 
fusion upon a rise in calcium concentration (Medina et al., 2011). Thus, the identification 
of compounds which promote clearance in MLIV cells by using cell-based High Content 
(HC) screening of drugs (including FDA-approved molecules) may represent a novel 
therapeutic approach to clear lysosomal storage in Mucolipidosis type IV.  
Results and discussion 
1. (HC)-screening TFEB relocator molecules in MLIV patient fibroblasts 
We have recently described a new lysosomal signaling involving TRPML1 during nutrient 
starvation. By using a siRNA-mediated High Content screening to identify the 
phosphatase(s) that dephosphorylates and activates TFEB, we have found that inhibition 
of the Ca2+-activated serine/threonine phosphatase calcineurin prevents the nuclear 
translocation of TFEB in starved cells. Moreover, by using a genetically-encoded 
78 
 
lysosomal Ca2+ sensor fused to TRPML1 (GCaMP-ML1), we found that upon nutrient 
starvation the activity of this channel increases, suggesting that starvation triggers the 
release of microdomains of Ca2+ from the lysosome (Medina et al., 2015). In agreement 
with these data, TRPML1 overexpression or agonist-mediated activation of TRPML1 
induce TFEB nuclear translocation (see Chapter 1 Fig. 10 a, b). Thus, starvation specifically 
induces lysosomal Ca2+ release through TRPML1 generating a Ca2+ microdomain that is 
responsible for calcineurin activation and TFEB de-phosphorylation in the proximity of 
the lysosomal membrane (Medina et al., 2015). As TFEB transcriptionally regulates 
autophagy and lysosomal exocytosis, we investigated whether the modulation of this 
newly identified lysosomal signaling pathway, involving TRPML1, modulates these 
functions. We found that TRPML1 overexpression induces autophagy as measured by the 
elevation of the autophagic marker LC3 (see Chapter 1 Fig. 16 b, c) and induces cellular 
clearance in multiple sulfatase deficiency (MSD), a neurodegenerative LSD (Medina et al., 
2015) (Medina et al., 2011). Conversely, human MLIV-affected fibroblasts presented a 
reduction in starvation- mediated TFEB nuclear translocation, impaired lysosomal 
exocytosis (Medina et al., 2011) and accumulated autophagic substrates such as p62 and 
NBR1 (Vergarajauregui et al., 2008a). Our previous data demonstrated that TRPML1 
could be targeted to promote clearance through the activation of TFEB (Medina et al., 
2011). In an MLIV disease context this cannot happen and alternative strategies need to 
be investigated. By combining a TFEB nuclear translocation assay and (HC) imaging we 
previously collected compounds able to induce TFEB nuclear translocation in HeLa cells. 
The next step was to assay them again to understand which of them have a mechanism 
of action that relies on TRPML1 activity. To do so, we developed a (HC) imaging assay to 
follow endogenous TFEB localization in both WT and MLIV human fibroblasts. 
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In order to identify whether previously identified compounds inducing TFEB nuclear 
translocation may promote the same nuclear translocation in TRPML1 depleted cells, we 
screened 150 TFEB relocators in human MLIV fibroblasts. We screened for the ability of 
these 150 compounds to induce endogenous TFEB nuclear translocation in both WT and 
GM02526 MLIV patient cells after 3 hours of treatment. The plates were analysed using 
Columbus software (© Copyright 2008-2017 PerkinElmer). We projected a script which, 
with the help of macros, segmented the cells in two regions (cytoplasm and nucleus). In 
figure 1 there is an example of the macro used for this analysis and in table 2, in Tables 
paragraph at the end of this chapter, is reported the complete script sequence (Fig. 24, 
tab. 4).  
 
Figure 24: Example of Columbus macro. (a) Human fibroblasts treated with Torin1, cells were then stained 
with endogenous TFEB (in green). (b) Same figure showed in panel a, with different colors are highlighted 
cells identified by Columbus software. The object (cells) touching the edges of the field where excluded 
from the analysis.  
 
The mean fluorescence of nuclear and cytoplasmic regions was calculated by the 
software. The selection of the Hits was based on the percentage of the cells that showed 
a high nuclear TFEB fluorescent intensity 3 standard deviation above the positive control 
represented by Torin1. Interestingly, we found that only 2 (compound 28 and compound 
31) out of 150 compounds were able to induce endogenous TFEB nuclear translocation 
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independently of the presence of MCOLN1 (fig. 25), confirming the major role of TRPML1 
in the regulation of TFEB and therefore lysosomal function. 
 
Figure 25: (HC)-screening of 150 TFEB relocator molecules in MLIV cells. (a) distribution of the mean value 
of % of nuclear TFEB, in the dotted box the two HITs are highlighted, the two Hits were selected since their 
value of % of nuclear TFEB was above 3 standard deviation. (b) The screening was performed in triplicate 
and the plots showed the correlation analysis among the 3 replicas. 
 
Since TFEB nuclear translocation is also regulated by the activity of mTORC1 complex, we 
asked whether the TFEB nuclear translocation induced by these two hits may be the result 
of mTORC1 inhibition. However, compound testing in a high content assay measuring the 
phosphorylation of a second level mTORC1 substrate, the ribosomal protein S6 (S6), did 
not show any reduction in such phosphorylation (fig. 26), indicating that these 
compounds induce TFEB nuclear translocation in both a MCOLN1 and mTORC1 




Figure 26: mTOR activity is not altered by compound 28 and 31 treatments. This figure showed 
immunofluorescence against endogenous phosphorylated residues of S6 ribosomal protein (S235/236) 
conjugated with a 594nm secondary antibody. Is clear from the image that the huge effect on mTOR 
inhibition was given by Torin1 which was used as positive control. The plot on the right showed the 
quantification of fluorescent intensity inside cytoplasm, the experiment was performed in triplicate.  
 
Furthermore, since our main purpose was the identification of compounds able to 
promote cellular clearance in human MLIV fibroblasts, we analysed relevant pathological 
features observed in cells, such as autophagy impairment, lipofuscin accumulation and 
cholesterol storage (Vergarajauregui et al., 2008a, Soyombo et al., 2006). Thus, we first 
confirmed that autophagic substrates such as P62 accumulate in human MLIV fibroblast 
(Vergarajauregui et al., 2008a). Interestingly, we also found that another autophagic 
substrate, NBR1 (Kirkin et al., 2009), accumulates in the insoluble fractions of MLIV 
protein extracts (fig. 27 a). In addition, by using flow cytometry, we found that MLIV 
fibroblasts also show an elevation of auto fluorescence, suggesting that our cellular 




Figure 27: Development of secondary assays. (a) Western blots of insoluble fraction of human fibroblast ctr 
and GM02526, the bar plot represents the quantification of 3 independent experiment. (b) Bar plot 
showing the increase of auto fluorescent material stored in MLIV cells (GM02526) compared with WT cells. 
Using the BD FACS Aria III cells were excited with 488nm laser then the emission with 2 different filters was 
measured. In green is reported the emission with FITC (530/30nm) in red the emission with PerCP-A 
(695/40nm). The plot showed the average of mean fluorescent intensity from 3 different experiment. 
 
MLIV is characterised not only by the accumulation of autophagic cargo but also lipids. 
Indeed, by using a novel reporter of cholesterol accumulation PFO-GST (Kwiatkowska et 
al., 2014) in human MLIV cells (GM02526 and GM02527) and WT, we also found a 
significant increase of such lipid in disease cells compared with WT counterpart. We used 
the latter results to develop a second (HC)-screening assay to test the ability of our 
compounds to reduce cholesterol storage in MLIV cells (see sub-paragraph 2).  As positive 
control, we used the cholesterol-depleting compound cyclodextrin, that has been shown 
to reduce cholesterol accumulation in Niemann Pick C patient cells (Rosenbaum et al., 
2010).  Starting from this characterization we decided to test the selected Hits in these 
secondary assays. First of all, we tested the ability of the 2 compounds to induce 
autophagic substrate clearance (p62 and NBR1 cargo (Lamark et al., 2009)) and we found 
83 
 
that only the compound 28 was able to reduce both p62 and NBR1 accumulation at 
different time-points in human GM02526-MLIV fibroblasts (fig. 28).  
 
Figure 28: Compound 28 ameliorates autophagic phenotype of MLIV cells. (a) Western blot showing the 
decrease of autophagic cargo p62 and NBR1 after cmp.28 treatment (24 and 48 hours) on insoluble fraction 
from GM02526 patient cell line. The bar plot on the right showed the quantification of 3 different 
experiment. 
 
Furthermore, we tested also the compound 28 for cholesterol clearance in two different 
MLIV patient fibroblast cell lines (GM02526 and GM02527). While with cyclodextrin we 
observed a clear cholesterol reduction, the efficacy of compound 28 was not so elevated 







Figure 29: Cmp.28 partially decreases cholesterol accumulation in GM02526 cell line. To emphasize the 
cholesterol staining the cells were pretreated with U18666A. Immunofluorescence with PFO-GST to stain 
the cholesterol accumulation in MLIV cells. The experiment was performed in triplicate.  
 
While performing our secondary assay we observed some toxicity for compound 28. 
Thus, in collaboration with bioinformatic core at TIGEM we tried to identify potential 
analogues by using a new computational approach called MANTRA which exploits 
similarities between drug-induced transcriptional profiles already available in public 
databases (Carrella et al., 2014). We run the analysis to screen for drugs presenting a 
similar transcriptional profile to the one generated by compound 28 (fig. 30 a). Among 
the network of drugs with a significant “proximity” to Compound 28 hit we generated a 
sub-library of 121 compounds. We screened this new sub-library formed by compound 
28 analogues for TFEB nuclear translocation. We screened both wild type and MLIV 
fibroblast and finally we selected the common Hits. We identified 2 out of 121 which 
promote TFEB nuclear translocation in both cell lines (fig. 30 b, c, d).  Together, we have 
identified compound 28 which was able to induce TFEB nuclear translocation and 
clearance of autophagic substrates in MLIV cellular models. In addition to act in the 
absence of TRPML1, this compound hit is not inducing TFEB nuclear translocation through 
the inhibition of mTOR. In addition, by looking among compound 28 analogues we 
identified other two compounds which could exploit the same effect of compound 28 but 
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with less toxicity. Further analysis of the signaling activated by these compounds is 






Figure 30: (a) Transcriptional network generated with MANTRA starting from compound 28. (b) Analogues 
of compound 28 were tested on human wild type fibroblasts (Hf Ctr) for 3 hours, the plot shows the 
distribution of the mean value of % of nuclear TFEB, in the dotted box the 7 HITs are highlighted, Hits were 
selected since their value of % of nuclear TFEB was above 3 standard deviation from DMSO. (c) Analogues 
of compound 28 were tested on MLIV fibroblasts (GM02526) for 3 hours, the plot shows the distribution 
of the mean value of % of nuclear TFEB, in the dotted box the 2 HITs are highlighted. Hits were selected 
since their value of % of nuclear TFEB was above 1 standard deviation from DMSO. (d) Representative 
images of compound 18 and 20 which promote TFEB nuclear translocation in both cell lines. Dmso and 
Torin1 have been used as negative and positive control respectively for TFEB translocation. 
  
2. (HC)-screening of whole FDA library to identify compounds that reduce 
cholesterol accumulation in MLIV fibroblasts 
The second primary (HC)-screening assay was based on a cholesterol reduction assay. It 
has been reported that MLIV fibroblasts accumulate cholesterol within lysosomes 
(Soyombo et al., 2006), thus we decided to design a cellular based assay focused on 
cholesterol reduction. To stain cholesterol we used a novel approach based on the use of 
the protein toxin of microbial origin perfringolysin O conjugated with GST (PFO-GST) 
(kindly provided by Dr. Sobota from the Nencki Institute of Experimental Biology) 
(Kwiatkowska et al., 2014). PFO-GST specifically recognizes free cholesterol avoiding the 
drawbacks of other dyes such as filipin. PFO-GST labelling can be performed in fixed 
samples making this approach highly suitable for (HC)-screening. In addition, the cells 
could be permeabilized and co-stained with other markers such as LAMP1, and therefore 
we can measure the quantity of cholesterol accumulation within the lysosome. As part of 
the assay validation, we used this approach in two MLIV patient cell lines (GM02526 and 
GM02527) as well as in control fibroblasts. We designed a specific script to quantify PFO-
GST staining (fig. 31) and analysed several parameters to select the one that offers the 
best signal window to perform a screening (fig. 31 a). First of all, we evaluate the 
fluorescent intensity of 488nm channel in the whole cytoplasm, without having huge 
variation among cell lines and treatments, thus we decided to measure the fluorescence 
intensity restricted to the spot region (highlighted in red in figure 31). The complete script 
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sequence is reported in table 3 in Tables paragraph at the end of this chapter (fig. 31, 
Tab. 5).  
 
Figure 31: Example of Columbus macro. (a) Human fibroblasts GM02527 stained with PFO-GST with white 
line are highlighted cell regions (nucleus and cytoplasm). (b) same image reported in panel a. In red is 
highlighted area occupied by cholesterol storage. The object (cells) touching the edges of the field where 
excluded from the analysis.  
 
To further increase the signal window, we pre-treated the cells with U18666A, this drug 
inhibits three membrane-bound enzymes in sterol synthesis that catalyse very different 
reactions (a ring-forming cyclase, an isomerase, and a reductase), furthermore, it blocks 
the egress of cholesterol and other molecules from lysosomes and the movement of 
cholesterol from the plasma membrane to the endoplasmic reticulum. For all these 
reasons, it represents a versatile chemical tool used to address questions on control of 
cholesterol biosynthesis and intracellular trafficking of cholesterol (Cenedella, 2009, 
Liscum and Faust, 1989). As positive control of cholesterol clearance, we used 
cyclodextrin that has been reported to reduce cholesterol storage in Niemann pick type 





Figure 32: Selection of (HC)-screening parameters. (a) Immunofluorescence on control fibroblast (HF Ctr) 
and MLIV (GM02527, GM02526) untreated or pretreated with the cholesterol accumulating-drug U18666A 
and stained with recombinant PFO-GST. The plot on the right showed the intensity of 488nm emission in 
the area of the spot, the experiment was performed in triplicate b – Cyclodextrin reduces cholesterol 
accumulation in both WT and MLIV fibroblasts. The plot on the right showed the intensity of 488nm 
emission in the area of the spot, the experiment was performed in triplicate. 
 
After the validation and selection of our cholesterol assay parameters, we have screened 
the full Prestwick Chemical Library®, composed by a collection of 1280 FDA-approved 
drugs, in the MLIV cell line GM02527.  The screening was performed in triplicate, each 
plate was treated 16 hours with U18666A, then the drugs were added for 48 hours. We 
obtained 9 total HITs. Subsequently, FDA101 was discarded since visual inspection of the 
acquired images revealed that this drug is auto-fluorescent in both the 405nm and 
488nm channels. Figure 33 and figure 34 show some images coming from the screening 
and a complete list of the selected HITs is available in table 1 at the end of this chapter in 
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Table paragraph (Fig. 33 and 34, and table 6). These hits will need further validation to 
understand the potential mechanism of action reducing lipid accumulation. 
 
Figure 33: Screening output. (a, b, c, d) Plot showing the correlation among the 3 replicas of the screening for each 
plate. (e) bar plot representing the compound effect in reducing cholesterol spot area. In black and grey are reported 





Figure 34: Screening output, representative images. GM02527 MLIV fibroblast stained with PFO-GST (in green) and 
DAPI (blue). On the top are reported the DMSO and the cyclodextrin treated cells and then follows representative 
image of the selected hits.  
 
Conclusion 
We have used the knowledge resulted from the first chapters of this work to develop 
strategies to screen for FDA compounds able to ameliorate the cellular phenotype of 
human MLIV fibroblasts. By screening TFEB inducers on MLIV cells we identified that only 
one drug, Compound 28, out of 150 tested was able to induce TFEB nuclear translocation 
in cells depleted of TRPML1. Moreover, this compound hit also was able to promote the 
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clearance of autophagic substrates such as p62 and NBR1 that accumulates in MLIV cells. 
During our experiments, we have observed that this drug affects cell viability, thus, we 
tried to identify potential analogues by using a new computational approach developed 
by our Bioinformatic core at TIGEM called MANTRA that exploits similarities between 
drug-induced transcriptional profiles already available in public databases (Carrella et al., 
2014). Starting from this analysis we generated a sub-library composed by 121 
compounds which showed similar transcriptional profile to the one generated by 
compound 28. We tested this library for TFEB nuclear translocation in wild type and MLIV 
fibroblasts and we selected 2 out of 121, these compounds will be tested in the next 
future by their ability to reduce pathological accumulation of autophagic substrates and 
lipids (using the developed clearance assays described in results sub paragraph 1). In 
addition, since compound 28 induces clearance in a TRPML1- and mTOR-independent 
manner, we will investigate other clearance mechanisms that may be involved on the 
activity of compound 28 and their analogues such as alternative pathways for autophagy 
induction or lysosomal exocytosis (Medina et al., 2011). Since lysosomal exocytosis 
requires calcium, we plan to use calcium chelators such as BAPTA-AM together with 
compound 28 to block compound 28-mediated activity (i.e. induction of TFEB nuclear 
translocation). In addition, we will test whether compound 28 induces lysosomal 
exocytosis using a specific assay that measure the appearance of the lysosomal 
membrane protein LAMP1 in the plasma membrane.  
As a second approach to repurpose FDA drugs promoting clearance in MLIV cells, we 
developed a new (HC)-screening cholesterol clearance assay. We have isolated 8 
compounds hits that consistently reduce cholesterol accumulation in MLIV fibroblast. 
These hits will be confirmed by their ability to reduce cholesterol in a dose-response 
manner to determine selectivity and potency (EC50s). Then, similarly to the previous 
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paragraph (results sub paragraph 1) we will use secondary assays to investigate whether 
they are able to reduce pathological parameters such as accumulation of autophagic 
substrates and lipofuscin storage. Moreover, we will investigate whether these 
compounds act through the activation of clearance pathways such as autophagy and/or 
lysosomal exocytosis.  Together these (HC)-screenings allowed us to identify 12 potential 
compounds that could be repurposed to new therapeutic applications. They restore TFEB 
signalling and promote lipid storage clearance in human fibroblast from MLIV patients or 
for other lysosomal storage disease in which TRPML1 activity have been compromised 
like Nieman-Pick Type C disease (NPC). All the results presented in this chapter required 
additional work, in particularly regarding the mechanism of action, but represent a 
powerful and promising starting point that take advantage from using already approved 
compounds which made them closer respect to unknown compounds for a potential cure 
for MLIV and other LSDs.   
Methods  
Drug treatments 
For the (HC)-screening assay all the drug treatments were performed using a robotic 
liquid handling station, Hamilton STARLet. The original compound plates 10mM 
(Prestwick chemical library or 150 TFEB relocator drugs composed by Prestwick and 
Selleck chemical libraries) in DMSO were diluted to a final concentration of 100µM in 
culture medium without serum. From this plate, 5µl were added directly on cells that 
have been plated the day before in 45µl. All drug treatments were performed in 384 well 
plate using a final concentration of 10µM.  
Cell culture 
 HeLa TFEB GFP were previously described (Settembre et al., 2012) and cultured in RPMI 
supplemented with 10% fetal bovine serum, 200uM L – glutamine, 100uM sodium 
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pyruvate, 1mg/ml G418, 5% CO2 at 37°C. Human fibroblasts from Mucolipidosis type IV 
(MLIV) patients were purchased from the Coryell Institute: GM02526 (Genotype 
Δ6432/486-2 AG), GM02527 (Genotype 486-2 AG/486-2 AG), GM02048 
(Genotype Δ6432/486-2 AG) and cultured in DMEM supplemented with 15% fetal 
bovine serum, 200uM L – glutamine, 5% CO2 at 37°C.  
Antibodies and western blotting  
For western blots, the following antibodies were used: B-Actin (AC-15, cat. A5441, 
1:4000), NBR1 (cell signalling cat. 9891, 1:1000), p62 (BD cat. 610833, 1:1000). Total cell 
lysate was prepared by solubilization in TRIS HCl 10mM and 0.2% SDS supplemented with 
protease and phosphatase inhibitor (SIGMA). Soluble and insoluble fraction were 
generated as previously described (Vergarajauregui et al., 2008a). Protein concentration 
was determined by the Bradford method. 
After SDS-PAGE and immunoblotting the protein recognised by the specific antibody was 
visualized by chemiluminescence methods (Luminata Crescendo Western HRP substrate, 
Millipore) using peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies 
(Calbiochem). Membranes were developed using a Chemidoc UVP imaging system (Ultra-
Violet Products Ltd) and densitometric quantification was performed in unsaturated 
images using ImageJ (NIH).  
Immunofluorescence  
For immunofluorescence, the following antibodies were used: TFEB (cell signalling cat. 
4240, 1:200), p-S6 ribosomal protein (S235/236) – Alexa 594 (cell signalling cat. 9865s 
1:200). Cells were fixed with PFA for 10 minutes on ice and permeabilized in 0.1% (w/v) 
saponin, 0.5% (w/v) BSA and 50mM NH4Cl in PBS (blocking buffer). For TFEB staining the 
blocking buffer was prepared with Triton X-100 0.05%. Cells were incubated with the 
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indicated primary antibodies for 1 hour and subsequently incubated with secondary 
antibodies. Images were acquired using Opera system from PerkinElmer and for image 
analysis was used Columbus software (Columbus 2.6.0.127073 © Copyright 2008-2017 
PerkinElmer).  
PFO-GST assay 
On experiment day, cells were seeded in 384 well-plate, after 8 hours from seeding 
4µg/ml of U18666A were added to cells for 16 hours. After U18666A pre-treatment the 
cells were treated for 48 hours as described in subparagraph “Drug treatments” of this 
chapter. Cells were then fixed in 3% paraformaldehyde (PFA) for 30 minutes at room 
temperature. PFA was quenched with an incubation with 0.1M glycine solution in PBS for 
5 minutes at room temperature. Cells were then permeabilized with 0.05% Triton X-100 
in PBS for 10 minutes and blocked 30 minutes in 3% fish gelatine (this last step was 
repeated twice). PFO-GST was prepared 5µg/ml in 0.2% fish gelatine and added on cells 
for 45 minutes. After 3 washes the antibody against GST (Rockland) was added for 1 hour, 
subsequently after 3 washes the secondary antibody Alexa 488 was added for 45 minutes. 
Images were acquired using Opera system from PerkinElmer and for image analysis was 
used Columbus software (Columbus 2.6.0.127073 © Copyright 2008-2017 PerkinElmer). 
Auto fluorescence measurement by FACS 
Cells were seeded in a 6 well plate, after seeding the cells were detached and 
resuspended in FACS buffer (2mM EDTA, 1% FBS, 0.1% Trypsin). Before FACS analysis the 
cells were filtered with a pre-separation filter with a cut off of 20/30µm. The instrument 
used was BD FACS Aria III. The cells were loaded into the instrument using a nozzle of 
130µm and the auto florescence of the cells was read using excitation laser 488nm and 2 
emission filter PerCP (695/40nm) and FITCH (530/30nm). The auto fluorescence intensity 







Table 4: List of the positive HITs obtained from the (HC)-screening of Prestwick Chemical Library® 
DRUGS Avarage spot Area Std dev Vitality 
FDA101 237,38 2,98 69% 
FDA102 442,73 34,39 103% 
FDA103 484,23 34,36 106% 
FDA104 498,48 9,48 100% 
FDA301 416,42 51,50 97% 
FDA302 426,49 51,97 110% 
FDA303 469,76 11,84 83% 
FDA401 369,71 135,10 76% 





Table 5: Script sequence used for the (HC)-screening of results sub-paragraph 1. In the table below are 











Exp1Cam1 Method: B 
Output Population: Nuclei 
ROI: None Common Threshold: 0.15 
  
Area: > 100 µm² 
  
Split Factor: 10 
  
Individual Threshold: 0.3 
  





Method: Common Filters 
Output Population: Nuclei 
Selected 





Exp2Cam1 Method: A 
  
Nuclei: Nuclei 






Method: Common Filters 
Output Population: 
SELECTED CELLS 









Method: Resize Region 
[%] 
Output Region: ALL 
Cytoplasm 
Region Type: Cytoplasm 
Region 
Outer Border: 0 % 








Exp2Cam1 Method: Standard 
Output Properties: TFEB 
INT NUCLEUS Population: 










Exp2Cam1 Method: Standard 
Output Properties: TFEB 
INT CYTOPLASM 
Population: 








Method: Filter by Property 
Output Population: Cells 
Nuclear TFEB 








Method: By Formula 
Output Property: ratio 




Variable A: TFEB INT 
NUCLEUS Mean 
Variable B: TFEB INT 
CYTOPLASM Mean 
Define 
Results Method: List of 
Outputs 
    
Population: 






Nuclear TFEB  
  
Population: 
SELECTED CELLS  
Number of Objects 

















Variable A: Cells 
Nuclear TFEB - 
Number of Objects 
Variable B: 
SELECTED CELLS - 
Number of Objects 
Output Name: % 









Table 6: Script sequence used for the (HC)-screening of results sub-paragraph 2. In the table below are 
listed in sequence all the steps and parameters used to perform the analysis on Columbus. 
Input 
Image 
Stack Processing:  
Individual Planes 




Channel: Exp1Cam1 Method: B 
Output Population: 
Nuclei 
ROI: None Common Threshold: 0.8 
  
Area: > 30 µm² 
  
Split Factor: 7.0 
  
Individual Threshold: 0.4 
  Contrast: > 0.1 
Find 
Cytoplasm Channel: Exp2Cam3 Method: F 
  
Nuclei: Nuclei Membrane Channel: Exp2Cam3 





Method: Common Filters 
Output Population: 
Nuclei Selected Remove Border Objects 
Region: Cell 
Find Spots 
Channel: Exp2Cam1 Method: B 
Output Population: 
Spots 
ROI: Nuclei Selected Detection Sensitivity: 0.5 
  
Splitting Coefficient: 0.07 
  
















Selected Method: Standard 
Output Properties: 












Region Type: Cytoplasm 
Region 
Outer Border: 5 % 
Inner Border: 50 % 
Find Spots 
(2) Channel: Exp2Cam1 Method: B 
Output Population: 
Spots ring 
ROI: Nuclei Detection Sensitivity: 0.5 
  
Splitting Coefficient: 0.5 
  





















Corrected Spot Intensity: 
> 600 
Spot Area [px²]: > 50 
Boolean Operations: F1 
and F2 
Define 
Results Method: List of 
Outputs 















Number of Objects 
Total Spot Area: Mean 
Relative Spot 
Intensity: Mean 
Number of Spots: 
Mean 
Number of Spots per 














Variable A: Nuclei 
Selected - Total Spot 
Area Mean 
Variable B: Nuclei 
Selected - Relative 











Variable A: Spots 
Selected - Number of 
Objects 
Variable B: Nuclei 










Variable A: Spots 
Selected - Spot Area 
[px²] Sum 
Variable B: Nuclei 
Selected - Cytoplasm 
Area [µm²] Sum 
Output Name: Area 









Variable A: Nuclei 
Selected - Intensity 
Cytoplasm Exp2Cam1 
Mean Sum 
Variable B: Nuclei 
Selected - Cytoplasm 









Variable A: Spots ring 
- Spot Area [px²] 
Sum 
Variable B: Nuclei - 
Number of Objects 
Output Name: ring 
spot area mean 
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REDUCED NUMBER OF VESICLES WERE POSITIVE FOR DFCP1 GFP IN CELLS DEPLETED FOR TRPML1 (BAR PLOT ON RIGHT). 
(B) ARPE19 WERE TREATED OVERNIGHT WITH 30µM OF MLSI, AT SAME TIME WERE TRANSFECTED WITH DFCP1 GFP 
PLASMID. CELLS WERE STARVED FOR 180 MINUTES AND THEN NUMBER OF DFCP1GFP STRUCTURES WERE COUNTED. A 
REDUCED NUMBER OF VESICLES WERE POSITIVE FOR DFCP1 GFP IN CELLS WHERE TRPML1 ACTIVITY WAS INHIBITED (BAR 
PLOT ON RIGHT). (C) HEK293 DFCP1 GFP CELLS WERE SILENCED 72 HOURS WITH A SIRNA TARGETING A SCRAMBLE 
SEQUENCE AND ONE TARGETING TRPML1, THEN WERE STARVED 180 MINUTES. NUMBER AND SIZE OF DFCP1 GFP SPOTS 
WERE COUNTED AND REPORTED IN THE BAR PLOTS ON RIGHT. (D) QUANTITATIVE PCR ON HEK293 (LEFT) AND ARPE19 
(RIGHT) TO SHOW KNOCK DOWN EFFICIENCY OF TRPML1 SILENCING. ............................................................... 55 
FIGURE 15: (A) ARPE19 CELLS WERE TREATED WITH 30µM OF MK6-83 FOR 180 MINUTES, THEN AN IMMUNOFLUORESCENCE 
AGAINST ENDOGENOUS WIPI2 WAS PERFORMED, AS POSITIVE CONTROL I USED CELLS STARVED FOR 180 MINUTES. 
NUMBER OF SPOTS WERE COUNTED AND NORMALIZED ON CELL NUMBER, IN THE BAR PLOT ON THE RIGHT ITS REPORTED 
THE FOLD INDUCTION CALCULATED ON THE DMSO. (B) HEK293 CELLS WERE TREATED WITH 30µM OF MK6-83 FOR 180 
MINUTES, THEN AN IMMUNOFLUORESCENCE AGAINST ENDOGENOUS WIPI2 WAS PERFORMED, AS POSITIVE CONTROL I 
USED CELLS STARVED FOR 180 MINUTES. NUMBER OF SPOTS WERE COUNTED AND NORMALIZED ON CELL NUMBER, IN THE 
BAR PLOT ON THE RIGHT ITS REPORTED THE FOLD INDUCTION CALCULATED ON THE DMSO. (C) ARPE19 CELLS WERE 
TREATED WITH 30µM OF MK6-83 FOR 180 MINUTES, THEN AN IMMUNOFLUORESCENCE AGAINST ENDOGENOUS LAMP1 
AND LC3 WERE PERFORMED. DMSO AND TORIN1 WERE USED AS NEGATIVE AND POSITIVE CONTROL RESPECTIVELY. 
NUMBER OF SPOTS WERE COUNTED AND NORMALIZED ON CELL NUMBER, IN THE BAR PLOT ON THE RIGHT ITS REPORTED 
THE FOLD INDUCTION CALCULATED ON THE DMSO. (D) WESTERN BLOT OF INSOLUBLE FRACTION OF HUMAN FIBROBLAST 
CONTROL UNTREATED OR TREATED OVERNIGHT WITH MLSI, 180 MINUTES OF STARVATION AND GM02048 (MLIV CELL 
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PERCENTAGE OF CELLS THAT SHOWED MORE THAN 2 WIPI2 PUNCTA PER CELL. THE EXPERIMENT WAS PERFORMED TWICE.
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FIGURE 16: GENETIC OR PHARMACOLOGICAL ACTIVATION OF TRPML1 PROMOTES WIPI2 SPOTS. (A) ARPE19 CELLS 
TRANSFECTED WITH TRPML1 GFP AND STAINED WITH ENDOGENOUS LAMP1. WHITE BOX AND WHITE ARROW SHOW 
THE CORRECT LOCALIZATION OF TRPML1 ON LYSOSOMES. (B) ARPE19 CELLS WERE TRANSFECTED 24 HOURS WITH 
TRPML1 GFP OR TRPML1 DDKK GFP, THEN AN IMMUNOFLUORESCENCE AGAINST ENDOGENOUS WIPI2 WERE 
PERFORMED, ON THE RIGHT THE FIRST BAR PLOT ON THE TOP SHOW THE NUMBER OF WIPI2 SPOTS IN TRANSFECTED CELLS, 
THE SECOND PLOT ON THE BOTTOM SHOW THE MANDERS OVERLAP COEFFICIENT (MOC) BETWEEN WIPI2 AND THE GFP. 
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NUMBER OF SPOT PER CELL +/- STANDARD DEVIATION. (E) WESTERN BLOT OF HELA TREATED 72 HOURS WITH AN SIRNA 
TARGETING VAP-A/B OR WITH AN SIRNA SCRAMBLE, TO SHOW KNOCK DOWN EFFICIENCY. ................................... 58 
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WAS PERFORMED. NUMBER OF SPOTS WERE COUNTED AND NORMALIZED ON CELL NUMBER, IN THE BAR PLOT ON THE RIGHT 
IT IS REPORTED THE FOLD INDUCTION CALCULATED ON THE DMSO, THE EXPERIMENT WAS PERFORMED 3 TIMES. ....... 60 
FIGURE 18: (A) ARPE19 CELLS WERE STARVED WITH OR WITHOUT STO-609 AND CMDZ. AN IMMUNOFLUORESCENCE AGAINST 
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FED CONDITION. (B) ARPE19 WERE TREATED WITH STO6-09 AND BAPTA-AM IN COMPLETE MEDIUM OR STARVED IN 
CO-TREATMENT WITH STO6-09, BAPTA-AM. DMSO WAS USED AS CONTROL OF MTORC1 ACTIVITY, TORIN1 AND HBSS 
WERE USED AS CONTROL FOR MTORC1 INACTIVATION. AN IMMUNOFLUORESCENCE AGAINST PS6 RIBOSOMAL PROTEIN 
WAS PERFORMED, THE MEAN INTENSITY WAS MEASURED AND REPORTED IN THE BAR PLOT ON THE RIGHT. ................. 61 
FIGURE 19: PHARMACOLOGICAL ACTIVATION OF TRPML1 INDUCE AMPK PHOSPHORYLATION. (A) WESTERN BLOT SHOWING 
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ENDOGENOUS WIPI2 WAS PERFORMED. NUMBER OF SPOTS WERE COUNTED AND NORMALIZED ON CELL NUMBER, IN THE 
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